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Summary    
Summary 
Proteostasis refers to all those biological processes that control the biogenesis, 
folding, trafficking and degradation of proteins present within and outside the cell. 
The alteration of the proteostasis regulatory pathways can seriously affect cell 
function and cause the onset of diseases, including rare diseases such as Congenital 
Erythropoietic Porphyria (CEP) and Townes-Brocks Syndrome (TBS). 
CEP is caused by a deficiency in the fourth enzyme of the heme pathway, UROS. 
The most common pathogenic allele, C73R, generates an unstable protein with <1% 
of normal activity, leading to severe phenotypes. Although mouse models exist for this 
disease, the classical C73R mouse model has poor viability and chronic health issues, 
posing challenges for experimental setups. In order to generate an inducible 
humanized mouse model for CEP, we designed a novel single-insertion genetic switch 
to replace the mouse Uros allele with a conditionally controlled human mutant 
version. Human UROS replaces and rescues mouse UROS function and, upon 
tamoxifen induction of Cre recombinase, the allele is converted to express the mutant 
C73R version. To verify functionality of the system, we tested it in murine fibroblasts. 
CRISPR/Cas9 was used to introduce the construct into cells. The correct functioning of 
the system was validated at both DNA and protein levels. Moreover, FACS and HPLC 
analyses were performed to measure porphyrin levels and test the UROS activity. This 
cellular model, as well as the planned knock-in mouse model, will be novel tools to 
allow deeper studies into CEP and testing of potential therapies. 
TBS is caused by mutations in the zinc-finger transcriptional repressor SALL1 
and is characterized by a spectrum of malformations in the digits, ears, and kidneys. 
In order to elucidate SALL1 functions and regulation in the context of post-
translational modifications, proximity proteomics BioID methodology in combination 
with mass spectrometry made possible the identification of putative interactors of 
human SALL1. Among them, we found CBX4, an E3 SUMO ligase and a key member of 
the Polycomb Repressive Complex 1 involved in chromatin remodeling and gene 
silencing. We confirmed that SALL1 and CBX4 interact with each other at the protein 






and subsequent degradation via the ubiquitin proteasome system, SALL1 stabilizes 
and increases CBX4 protein levels. This affects the Pc nuclear bodies formation, which 
appear more abundant and bigger than in wild type cells. In addition, high levels of 
SALL1 increased the transcriptional repression capacity of CBX4 on some of its target 
genes. Interestingly, the SUMOylation of SALL1 seems to be necessary to enhance the 
transcriptional repression capacity of CBX4. Our data could contribute to understand 
the relationship underlying the interaction between SALL1 and CBX4, which could help 
to better understand the role of SALL1 during normal development and the 
pathogenesis of TBS. 
Altogether, the results obtained throughout this work could help to better 
understand the pathogenesis of both these rare diseases and could advance the 
development of new potential therapies. 
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Resumen    
Resumen 
El término proteostasis se refiere a todos aquellos procesos biológicos críticos 
para el buen funcionamiento de la célula. La alteración de las vías reguladoras de la 
proteostasis puede afectar seriamente la función celular y causar la aparición de 
enfermedades, incluidas enfermedades raras como el Síndrome de Townes-Brocks 
(TBS) y la Porfiria Eritropoyética Congénita (CEP).  
La CEP es causada por una deficiencia en la cuarta enzima de la vía de 
producción del grupo hemo, UROS. El alelo patógeno más común, C73R, genera una 
proteína inestable con menos del 1% de la actividad normal, lo que conduce a la 
acumulación de porfirinas y a fenotipos graves. El modelo clásico de ratón C73R tiene 
poca viabilidad y presenta problemas de salud crónicos, lo que plantea desafíos para 
su uso experimental. Para generar un modelo de ratón humanizado, inducible, 
mutante para CEP, diseñamos un nuevo interruptor genético de inserción única para 
reemplazar el alelo Uros del ratón con una versión controlada condicionalmente. El 
UROS humano reemplaza y rescata la función UROS del ratón y, tras la inducción con 
tamoxifeno de la recombinasa Cre, el alelo expresa la versión mutante C73R. Para 
verificar su funcionalidad, se testó el sistema en fibroblastos murinos. Se usó 
CRISPR/Cas9 para introducir la construcción en las células. El correcto funcionamiento 
del sistema fue validado tanto a nivel de ADN como de proteína. Se realizaron análisis 
FACS and HPLC para medir los niveles de porfirinas e investigar la actividad de UROS. 
Este modelo celular, así como el modelo de ratón knock-in planificado, serán 
herramientas novedosas para permitir estudios más profundos en CEP y probar 
posibles terapias. 
El TBS está causado por mutaciones en el represor transcripcional de dedos de 
zinc SALL1 y se caracteriza por un espectro de malformaciones en dígitos, oídos y 
riñones. Para dilucidar las funciones y la regulación de SALL1 en el contexto de las 
modificaciones postraduccionales, se utilizó un ensayo de proteómica de proximidad 
BioID en combinación con espectrometría de masas para identificar posibles 
interactores de SALL1 humano. Entre éstos, encontramos CBX4, una E3 SUMO ligasa 






remodelación de la cromatina y el silenciamiento génico. Confirmamos que SALL1 y 
CBX4 interactúan entre sí a nivel de proteína y que colocalizan en el nucleoplasma. Al 
modificar su ubiquitinación y su posterior degradación a través del proteasoma, SALL1 
estabiliza y aumenta los niveles de proteína de CBX4, afectando así la formación de 
cuerpos nucleares Pc que parecen más abundantes y más grandes. Además, altos 
niveles de SALL1 aumentan la capacidad de represión transcripcional de CBX4 en 
algunos de sus genes diana. Curiosamente, la SUMOilación de SALL1 parece ser 
necesaria para mejorar el efecto de represión transcripcional de CBX4. Elucidar la 
relación subyacente a la interacción entre SALL1 y CBX4, podría ayudar a comprender 
mejor el papel de SALL1 durante el desarrollo normal y en la patogénesis de TBS. 
En conjunto, los resultados obtenidos a lo largo de este trabajo podrían ayudar 
a comprender mejor la patogénesis de estas dos enfermedades raras y podrían ayudar 
en el avance del desarrollo de potenciales terapias. 
 
 



























1.1. Proteostasis: the maintenance of proteome 
equilibrium 
Proteostasis, is a blend word formed by ‘protein’ and ‘homeostasis’ and 
referred to all those biological pathways that control the biogenesis, folding, 
trafficking and degradation of proteins present within and outside the cell. 
Proteostasis, enables healthy cell, organismal development and aging, and protects 
against disease (Balch et al. 2008). To preserve proteostasis cells must ensure correct 
proteins folding and assembling, as well as appropriated abundance and 
compartmentalization (Jayaraj, Hipp, and Hartl 2020). Highly sophisticated 
mechanisms provide a tight regulation of those processes on multiple levels (Hartl, 
Bracher, and Hayer-Hartl 2011). 
Proteostasis network is a set of numerous interacting activities that keep 
proteins in a balanced equilibrium by maintaining their folding and regulating their 
expression and degradation (Figure 1). These pathways are critical processes for the 
proper functioning of the cell and comprise a wide range of general and specialized 
chaperones, folding enzymes, post-translational modifications and degradation 
components, as well as trafficking components, which can influence proteins 






Figure 1. Protein homeostasis processes. Proteostasis depends on the biogenesis, folding, 
post-translational modifications, trafficking and degradation of proteins present within and outside the 
cell to keep its proper functioning. Adapted from (Dissmeyer et al. 2019). 
 
The generation of a new protein is regulated by many factors involving 
transcription, translocation of mRNA out of the nucleolus and translation. When the 
new polypeptide chain emerges from the ribosome, it has to be properly folded. 
Molecular chaperones promote folding and maintenance within the cell, largely by 
minimizing misfolding and aggregation. Protein folding, unfolding, and refolding are 
highly dynamic processes constantly occurring throughout the lifetime of proteins. In 
fact, chaperones can participate in the folding of neo-synthesized proteins or interact 
with pre-existing proteins that may suffer denaturation upon acute stress. Specialized 
chaperones for various compartments of the cell such as the endoplasmic reticulum 
(ER) and mitochondria have also been reported (Brehme et al. 2014).  
Once proteins are folded, they can undergo numerous post-translational 
modifications that determine their function, localization, interaction with other 
proteins and half-life. These modifications could involve small chemical molecules as 
it occurs in phosphorylation, acetylation and methylation, or proteins could covalently 
modify other proteins as in the case of ubiquitin (Ub) (Hochstrasser 2009). Ub is a small 





Proteins similar to Ub, either in sequence or in their three-dimensional 
structure, form the family of Ub-like modifiers (UbL). Nearly 20 UbL proteins have 
been described in mammalian cells (Pirone et al. 2017). The main members of the UbL 
family include SUMO1-4 (Small Ub-related Modifier 1-4), NEDD8 (Neural precursor cell 
expressed developmentally down-regulated 8), ISG15 (Interferon-stimulated gene 
15), FAT10 (HLA-F-adjacent transcript 10), UFM1 (Ub fold modifier 1), Atg-8 and Atg-
12 (autophagy-related Ub-like modifier 8 and 12) and URM1 (Ub-related modifier 1) 
(Cappadocia and Lima 2018). 
1.1.1 Ubiquitin and Ubiquitin-like pathways  
The Ub and UbL pathways represent essential branches of the proteostasis 
network and play a central role in the management of misfolded and aggregated 
proteins. Ub and UbLs are conjugated to the substrates as result of sequential 
reactions catalysed by several enzymes (Figure 2). First, an E1 activating enzyme forms 
a transient thioester bond with the Ub C-terminal glycine residue, exposing the 
characteristic di-glycine motif present in most UbLs. Afterwards, the activated Ub is 
transferred to a cysteine residue located in the active site of an E2 conjugating 
enzyme. Ubiquitination is finalized by an E3 ligase, which catalyses conjugation of the 
UbL to the substrate, typically to a lysine residue (Bett 2016).  
Protein ubiquitination is a reversible process regulated by deubiquitinating 
enzymes (DUBs). The role of DUBs is the specific removal of Ub from substrates, which 
contribute to the activation and/or deactivation, recycling and localization of many 
regulatory proteins in different cellular processes (Farshi et al. 2015). Although 
modification by all the different UbLs follow the same reversible cycle, the enzymes 






Figure 2. Ubiquitination cycle. E1 activating enzyme forms a transient thioester bond with the 
ubiquitin C-terminal glycine residue. Afterwards, the activated ubiquitin is transferred to the active-site 
cysteine residue of an E2 conjugating enzyme. Ubiquitination is finalized by an E3 ligase, which catalyses 
conjugation of ubiquitin to the substrate, typically to a lysine residue. Eventually, deubiquitinating 
enzymes (DUBs) can remove ubiquitin from substrates. All UbLs undergo this 
modification/demodification cycle by means of enzymes specific for each UbL. 
 
 
Substrate proteins can be ubiquitinated by a single ubiquitin moiety or multi-
monoubiquitinated at different lysine residues. Ubiquitin may also form homotypic or 
heterotypic chains by modifying itself in any of the lysine residues in its sequence. 
Ubiquitin chains are homotypic if the same residue is modified during elongation, for 
instance K11-, K48-, or K63-linked chains. Chains are heterotypic if different linkages 
alternate at succeeding positions of the chain. Each moiety of the chain can be further 
ubiquitinated to form a branched structure. Moreover, ubiquitin moieties could 
undergo additional modifications as acetylation, phosphorylation or UbL molecules 
conjugation, among others, generating a great range of signals responsible for specific 
cellular outcomes. This intricate configuration system is known as the “ubiquitin code” 






Figure 3. The Ubiquitin code. Conceptual representation of some of the possible ubiquitin and 




Besides ubiquitination, SUMOylation represent the best-studied UbL 
modification and can compete with ubiquitination for modification of the same lysine 
residues. SUMO is also covalently attached to an acceptor lysine of target proteins. In 
general, many SUMOylation sites follow a consensus motif ψ–K–X–E/D (ψ is a 
hydrophobic amino acid, K is the target lysine, X is any amino acid and D/E is aspartic 
or glutamic acid), but in addition to this, different non-canonical consensus sequences 
have been described (Matic et al. 2010; Hietakangas et al. 2006). 
There are four SUMO isoforms in humans, designated SUMO1, SUMO2, 
SUMO3 and SUMO4. While SUMO1 is distinct from the other family members (47% 





sequence identity of 97% and are mostly referred to as SUMO2/3. SUMO4 shares 87% 
sequence identity with SUMO2 however, little is known about its expression and 
function (Bohren et al. 2004). SUMO1 and SUMO2/3 are ubiquitously expressed. The 
main target of SUMO1 is RANGAP1 (Ran GTPase‐activating protein 1), while SUMO2/3 
is normally present in the cells unconjugated and is rapidly attached to substrates 
under cellular stress conditions (Eifler and Vertegaal 2015). Indeed, SUMOylation 
levels are dynamically regulated by various stresses such as heat shock, hypoxia or 
nutrient depletion. While SUMO2/3 can form polymeric chains, SUMO1 is generally 
considered as a chain terminator when incorporated in SUMO2/3 chains (Enserink 
2015).  
Before to be attached on targets, a SUMO precursor protein is processed by 
SUMO proteases (SENPs) to expose the carboxyl-terminal di-glycine motif. Next, 
similarly to ubiquitin, the mature form of SUMO is first activated by the heterodimeric 
SUMO activating enzyme (E1) composed of SAE1 and SAE2 (also known as UBA2) and 
then transferred to the single SUMO E2 conjugation enzyme UBC9 (also known as 
UBE2I). Finally, the activity of SUMO E3 ligases is necessary for efficient conjugation of 
SUMO to its substrates. Since SUMOylation is a reversible process, SUMO proteases 
are also responsible of SUMO cleavage from its substrate. 
SUMO proteins could also interact with other proteins in a non-covalent way 
through specific recognition sequences called SUMO Interaction Motifs (SIMs), which 
can contribute to the mechanism and consequences of SUMOylation. SIMs are the 
predominant motifs that bind SUMO proteins and generally are composed of four 
hydrophobic residues that are flanked by acidic residues or residues that can be 
phosphorylated to generate negative charge (Merrill et al. 2010). SIMs are found in 
the SUMO activating enzyme UBA2, in all known SUMO E3s, in some SUMO substrates 
and receptors, as well as in some ubiquitin E3s called StUbLs (SUMO targeted Ubiquitin 
Ligases). This is a conserved subfamily of ubiquitin E3 ligases, which can specifically 
target and bind SUMOylated proteins facilitating their ubiquitination. Besides 
containing a RING domain required for their ubiquitination activity, members of this 
family possess multiple SIMs to target SUMOylated substrates for ubiquitination 





SUMO-ubiquitin chains on a protein either can act as a recruitment signal or can target 
proteins to the proteasome.  
Besides degradation, SUMOylation might affect the target protein in many 
different ways, including changes in localization, protein-protein interactions, protein 
activity and stability. While ubiquitination is generally linked to degradation, this is not 
necessarily the case for SUMOylation (Celen and Sahin 2020). For example, 
SUMOylation of Oct4 leads to significantly increased Oct4 stability and increased DNA 
binding (Wei, Schöler, and Atchison 2007). Regulatory factors responsible for 
chromatin remodelling and modification are also subject to SUMOylation, which alters 
their activities. For instance, SUMOylation enhances DNMT1 (DNA methyltransferase 
1) activity promoting DNA methylation (Lee and Muller 2009). Moreover, 
SUMOylation of HDAC1 (histone deacetylase 1) is required for its full transcriptional 
repression activities at defined promoters (David, Neptune, and DePinho 2002). 
SUMOylation is therefore involved in many biological processes, including regulation 
of transcription, DNA repair, immunity and development, among others (Talamillo 
et al. 2020; Garvin 2019).  
The imbalance of SUMOylation and deSUMOylation has been associated with 
the occurrence and progression of various diseases. Cancer development can be 
attributed to abnormal SUMOylation as consequence of the enhanced expression of 
the enzymes involved in the SUMO modification pathway (Seeler and Dejean 2017). 
Moreover, SUMOylation contributes to different neurological disorders such as 
Parkinson’s disease, Alzheimer’s disease and Huntington’s disease in which SUMO has 
been found to either enhance or protect against the aggregation of neuronal proteins 
(Yang et al. 2017).  
1.1.2 Degradation of misfolded proteins 
Protein folding is an intrinsically error-prone process that frequently results in 
toxic protein-protein interactions and that must be efficiently managed by the cellular 
proteostasis network. Several different pathways exist for carrying out these 
degradation processes. When proteins are unfolded or misfolded, they are typically 





associated protein degradation (ERAD). Autophagy can also be used as a proteostatic 
degradation mechanism (Figure 4). 
The UPS represent the primary pathway the cells use to recognize and clear 
soluble misfolded proteins. When misfolded proteins need to be degraded, they are 
typically tagged with a K48-linked polyubiquitin chain to mediate binding by ubiquitin 
receptors on the 26S proteasome (Rpn10/S5a and Rpn13) required for substrate-
mediated activation of the proteasome’s unfolding ability (Cundiff et al. 2019). The 
unfolded protein response (UPR) in the endoplasmic reticulum (ER) is activated by 
imbalances of misfolded proteins inside the ER. When incorrectly folded, proteins are 
retro-translocated to the cytosol and ubiquitinated for proteasomal degradation. 
Aggregated proteins that cannot be unfolded for proteasomal degradation 
may be removed by autophagy and lysosomal/vacuolar degradation. In mammalian 
cells, three types of autophagy have been described: macroautophagy, 
microautophagy, and chaperone‐mediated autophagy (CMA). Macroautophagy 
requires sequestration of substrates in a double membrane vesicle, which then fuses 
with lysosomes; microautophagy involves direct engulfment of cytosolic components 
by lysosomes. In CMA, substrates are recognized by chaperones and targeted to 






Figure 4. Unfolded protein response. Misfolded proteins are typically marked with K48-linked 
Ub chain and degraded by the proteasome (left panel). Three types of autophagy may remove proteins 
that cannot be unfolded for proteasomal degradation. Macroautophagy requires sequestration of 
substrates in a double membrane vesicle, which then fuses with lysosomes; microautophagy involves 
direct engulfment of cytosolic components by lysosomes. In chaperone‐mediated autophagy (CMA), 
substrates are recognized by chaperones and targeted to lysosomes for degradation (middle panel). 
Misfolded proteins inside the ER are retro-translocated to the cytosol, and ubiquitinated for 
proteasomal degradation (left panel). 
 
 
1.1.3 Proteostasis dysfunction and therapeutic strategies 
Mutations in genes involved in protein synthesis, folding, aggregation, 
autophagy, mitophagy, ER stress or the UPS can result in proteostasis dysregulation. 
These mutations could be inherited and differ in phenotypic severity from having no 
noticeable effect to embryonic lethality. Disease develops when these mutations 
significantly affect proteins making them more prone to misfolding, aggregation and 
degradation. If this effect only alters the mutated protein, the negative consequences 
will only be local loss of function. However, mutations can also cause dominant 
negative effects interfering with the function of wild type (WT) proteins. Differently, 
if mutations occur in a chaperone or a protein that interacts with many other proteins, 
dramatic global alterations in the proteostasis boundary will occur (Powers et al. 2009; 
Hipp, Park, and Hartl 2014).  
Two main strategies have been used for therapeutic development targeting 
the proteostasis network: pharmacologic chaperones and proteostasis regulators. 
Pharmacological chaperones are cell-permeant small molecules that bind to and 
stabilize target proteins. They are very specific and have effects on particular proteins. 
Most of the pharmacological chaperones are substrates or active site-directed 
competitive inhibitors and are very efficient at lower concentrations. However, a 
pharmacological chaperone cannot bind to all the variants present in a disorder 





and hence pass through the quality control system of the ER and traffic safely from 
there to the designated location. 
Instead, proteostasis regulators (PRs) work by manipulating signalling 
pathways, including the UPR, resulting in transcriptional and translational 
upregulation of proteostasis network components. PRs manipulate the system 
through different mechanisms. Some PRs negatively affect protein production to 
inhibit global protein generation. Other regulators are used to either increase the 
production of molecular chaperones or modify their function. Moreover, some PRs 
function by directly manipulating the proteasomal system either by increasing its 
activity when cells are under stress or through inhibiting the system to prevent 
premature degradation (Mohamed et al. 2017). 
Understanding how proteins function is essential to understanding how cells 
work. Model systems, including laboratory animals and cell-based systems, continue 
to have an important role in the identification of functional mechanisms that 
safeguard proteostasis and are essential to discover and develop novel and better 
drugs for the treatment of human diseases. Model systems of diverse misfolding-
prone disease proteins have so far revealed numerous chaperone and co-chaperone 
modifiers involved in proteostasis maintenance (Brehme and Voisine 2016). 
Furthermore, protein function is usually accomplished by interactions with other 
proteins. To unveil proteins behaviour and regulation can allow better predicting, 
preventing, diagnosing, and treating disease. 
1.2 Rare diseases 
Maintenance of cellular proteostasis is essential for cell functioning and 
survival. Alteration of proteostasis regulatory processes might severely affect cellular 
functions and might directly or indirectly be associated to the aetiology of many 
diseases, including those with very low prevalence (Osinalde et al. 2019). Rare 
diseases are those that affect a small number of people compared to the general 
population and specific issues are raised in relation to their rarity. In Europe, a disease 





may affect only one person in a million but, all together, rare disease patients 
comprise 6% to 8% of the EU population (Eurodis). Distribution of different types of 
rare diseases is illustrated in Figure 5. Rare diseases are often severe, chronic and 
progressive disorders. Although their signs are usually observed at birth or in 
childhood, over 50% of rare diseases, appear during adulthood (Orphanet). Because 
the number of people affected with any one specific rare disease is relatively small, 
the development of effective drugs and medical devices to prevent, diagnose, treat, 
or cure these conditions becomes extremely complicated.  
 
Figure 5. Distribution of different types of rare diseases. The pie chart represents rare disease 
categories and their frequencies, given as the percentage of the total number of rare diseases. 
Categories with a frequency < 4% were grouped into the category termed “Other diseases”. Categories 
and frequencies shown in the graph were extracted from information provided by the Genetic and Rare 
Diseases Information Center (GARD, rarediseases.info.nih.gov). Edited from (Osinalde et al. 2019). 
 
 
Rare diseases can have multiple causes. They are mostly inherited but may also 
arise as result of de novo mutations. Besides, some diseases may be acquired because 
of a toxic exposure, infection or radiation. Many, if not most, are caused by defects in 
a single gene, as in the case of the alpha 1 antitrypsin deficiency (AATD), in which 





ataxia, a neurological disorder caused by mutation in FXN gene that may also be 
accompanied by cardiac and other problems. Multiple different mutations in that 
single gene may result in disease with varying features or severity while, in other cases, 
mutations in a single gene can produce pleiotropic effects. For example, fragile X 
syndrome is caused upon transcriptional silencing of the FMR1 gene. Its product, the 
FMRP protein, is responsible for binding and repressing the translation of hundreds of 
mRNAs so potentially affecting multiple pathways (Osinalde et al. 2019). 
In some rare conditions, multiple genes may contribute collectively to the 
manifestations of the disorder. For instance, in the Williams-Beuren syndrome the 
gene responsible for the production of the elastin protein (ELN) is clearly identified as 
producing the cardiovascular problems, (Pober 2010). Further, some diseases may 
present variable expressivity and incomplete penetrance as in the case of the 
Neurofibromatosis type 1 and Marfan syndrome (Cimino and Gutmann 2018; Cañadas 
et al. 2010). 
Due to their wide aetiology, the diagnosis and treatment of rare diseases is not 
straightforward. The complex set of factors that influence particular genetic changes 
can make the diagnosis extremely difficult. Moreover, for many rare diseases, there 
are no available therapies and lack of adequate models makes even more difficult the 
study of new possible treatments.  
This work is focused on two different rare diseases: Congenital Erythropoietic 
Porphyria (CEP) and Townes-Brock Syndrome (TBS). Both diseases are extremely rare 
conditions caused by proteostasis alterations. However, the mechanisms underlying 
each condition are different. While CEP is caused by mutations that alter the stability 





premature truncation of the SALL1 gene, which triggers changes in the stability of 
partner proteins. 
1.3 Congenital Erythropoietic Porphyria: a metabolic rare 
disease 
1.3.1 Porphyrias and alterations in the heme biosynthesis pathway 
Porphyrias belong to a group of rare diseases characterized by a deficiency 
(inherited or acquired) of the enzymes involved in the heme biosynthesis, resulting in 
an abnormal accumulation of precursors molecules called porphyrins. Heme 
biosynthesis is a chemical process, constituted by a series of sequential reactions 
carried out by eight different intracellular enzymes localized in the mitochondria or 
the cytosol. Deficiency of each one of those enzymes cause a different type of 
porphyria (Figure 6). 
 
Figure 6. Schematic representation of heme pathway-associated porphyrias. Deficiencies of 
each one of the eight enzymes involved in heme biosynthetic pathway cause a different type of 







Porphyrias are classified as hepatic or acute and erythropoietic/cutaneous or 
chronic. This classification is based on the nature of the clinical manifestation and 
whether the primarily site of the precursor and/or porphyrins deposition is the liver 
or the erythron. The hepatic porphyrias include Acute Intermittent Porphyria (AIP), 
Hereditary Coproporphyria (HCP), Variegate Porphyria (VP) and ALA-Dehydratase 
Deficient Porphyria (ADP). Erythropoietic porphyrias include Congenital Erythropoietic 
Porphyria (CEP), Erythropoietic Protoporphyria (EPP) and X-Linked Protoporphyria 
(XLP). The Porphyria Cutanea Tarda (PCT) is considered to be a hepatocutaneous 
porphyria, as it presents with cutaneous lesions but the primarily site of porphyrin 
accumulation is the liver. PCT is the most common porphyria, with a prevalence of 1 
in 10.000. The most common acute porphyria, AIP, has a prevalence of approximately 
1 in 20.000, and the prevalence of the most common erythropoietic porphyria, EPP, is 
estimated in 1 among 50.000 to 75.000 persons. CEP is extremely rare, with an 
estimated prevalence of 1 in 1.000.000 or less, existing approximately 280 reported 
cases worldwide. ADP is also extremely rare with only six confirmed cases reported 
worldwide (Ramanujam and Anderson 2015).  
Heme is an important cofactor that plays an important role in the reactions of 
oxidation-reduction and in oxygen transport. It is necessary for the activity of a variety 
of hemoproteins, such as hemoglobin, myoglobin, respiratory cytochromes, and 
cytochrome P450 enzymes. The first enzyme in heme synthesis, δ-aminolevulinic 
synthase (ALAS), as well as the last three enzymes, coproporphyrinogen oxidase 
(CPOX), protoporphyrinogen oxidase (PPOX) and ferrochelatase (FECH) are 
mitochondrial, whereas δ-aminolevulinic acid dehydratase (ALAD), 
hydroxymethylbilane synthase (HMBS), uroporphyrinogen III synthase (UROS), and 
uroporphyrinogen decarboxylase (UROD) are localized in the cytosol.  
The synthesis of heme begins with the formation of δ-aminolevulinic acid (ALA) 
by ALAS from the amino acid glycine and succinyl-CoA from the citric acid cycle. This 
step represents the first and rate-limiting reaction in the pathway. In mammals, two 
different ALAS isoforms have been described, ALAS1 and ALAS2. Whereas ALAS1 is 
ubiquitously expressed in all tissues providing the basic needs of heme in the non-
erythropoietic cells, ALAS2 is expressed exclusively in the erythropoietic cells 





differentiation. In non-erythrocyte cells, ALAS1 is regulated by negative feedback of 
the free heme pool produced. In the erythrocytes, the expression of ALAS2 is regulated 
by erythroid-specific transcription factors, like GATA1, and, at the posttranscriptional 
level, by iron through a 5′ iron responsive element (IRE) that interacts with iron 
responsive proteins (IRPs). Under conditions of iron deficiency, the translation of 
ALAS2 mRNA is inhibited by IRPs binding to the 5′ IRE. However, when intracellular 
iron level increases, IRPs are degraded allowing the translation of ALAS2 mRNA 
(Chiabrando, Mercurio, and Tolosano 2014).  
In the heme synthesis process, schematized in Figure 7, the neo-formed ALA 
exits the mitochondria into the cytosol where two molecules of ALA condense to 
produce the pyrrole ring compound, porphobilinogen (PBG). The next step of the 
pathway involves condensation of four molecules of PBG, aligned to form the linear 
hydroxymethylbilane (HMB). HMB is then closed to form an asymmetric pyrrole ring 
D called uroporphyrinogen III (URO III). Next, this is modified to produce 
coproporphyrinogen III (COPRO III). Following its synthesis, COPRO III is transported 
into mitochondria and decarboxylated to form the protoporphyrinogen IX. Finally, 
protoporphyrinogen IX is converted to protoporphyrin IX. The final reaction involves 







Figure 7. Schematic representation of the heme biosynthesis pathway. Enzymes are indicated 
in dark red, while the respective substrates are reported in black. ALAS, CPOX, PPOX and FECH are 
mitochondrial, whereas ALAD, HMBS, UROS and UROD are localized in the cytosol. 
 
 
1.3.2 Congenital Erythropoietic Porphyria: a rare disease based on 
protein stability alterations 
CEP (ICD-10 #E80.0; MIM #263700), also known as Gunther’s disease, is an 
extremely rare disease inherited as an autosomal recessive trait. It is caused by an 
inborn error in the heme biosynthesis, mostly derived from the deficient activity, 
although not complete absence (<1 to ~10% of normal activity), of the fourth cytosolic 
enzyme of the pathway, UROS (EC 4.2.1.75).  
As shown in Figure 8, UROS catalyses the rapid cyclization of most of the linear 
HMB, inverting the configuration of one of the four aromatic rings and leading to the 
formation of URO III. In normal conditions, a little amount of HMB suffers a 
spontaneous closure resulting into uroporphyrinogen I (URO I). URO I and III can then 
follow into the biosynthesis chain as substrates for the next enzyme of the pathway, 





(coproporphyrinogen I) and COPRO III, respectively. While URO III and COPRO III are 
proper substrates for the subsequent reactions of the pathway, URO I and COPRO I 
are accumulated in the tissues and excreted in urine and faeces. In CEP, the markedly 
reduction of the UROS activity leads to the specific and massive accumulation of type 
I porphyrins, URO I and COPRO I, which result toxic and are responsible for the 
symptoms. 
 
Figure 8. Uroporphyrinogen formation. The closure of the HMB by UROS leads to the 
formation of uroporphyrinogen III isomer, while the spontaneous closure produces the isomer I. The 
red squares highlight the different configuration of the ring D. Adapted from (Bhagavan N. V., Chung-
Eun Ha 2015). 
 
 
Patients are either homozygous or composed heterozygous and the clinical 
severity is mostly mutation-dependent. Nevertheless, cases of variable expressivity 





hemolytic anemia with associated splenomegaly are the main symptoms of CEP. In the 
bone marrow, it has been observed that developing erythropoietic cells contain large 
amounts of porphyrins. Under fluorescent microscope, most normoblasts show 
localized red fluorescence heme-containing inclusion bodies into the nucleolus. The 
overproduction of porphyrin isomers I, accumulated mainly in erythroid cells, is 
associated with dyserythropoiesis, poikilocytosis, and bone marrow erythroid-
hyperplasia (Merino, To-Figueras, and Herrero 2006; Katugampola, Badminton, et al. 
2012).  
The electronic configuration of porphyrins endows them of photochemical 
properties that explain porphyrin phototoxicity. In fact, porphyrins are excited by 
visible and ultraviolet (UV) light (excitation 490 nm, emission 650 nm). Hemolysis 
causes porphyrins release into the plasma with subsequent deposits in the tissues. 
Porphyrins accumulation induces photodynamic reactions that stimulate the 
production of reactive oxygen species (ROS), which directly damage tissues and 
indirectly promote a proinflammatory response. The severity of cutaneous reaction 
depends on porphyrin amount in the tissue and the degree of light exposure (Di Pierro, 
Brancaleoni, and Granata 2016). 
CEP photosensitivity starts early in life and causes a series of cutaneous 
wounds such as vesicular or bullous eruptions in the skin exposed to light (Figure 9). 
Ultimately, continuous injuries and secondary skin infections with scars and 
hyperpigmentation can lead to severe mutilation of fingers, hands, ears, lips and nose. 
Other characteristic symptoms are porphyrin accumulation in bone marrow, plasma 
and urine, hypertrichosis or hirsutism (abnormal amount of hair growth over the body 
and excessive body hair on parts of the body where hair is normally absent or minimal, 
respectively) and erythrodontia (red discoloration of teeth) (Erwin et al. 1993).  
1.3.3 Diagnosis and treatment of Congenital Erythropoietic 
Porphyria  
CEP diagnosis usually occurs in childhood from the early onset of severe skin 
photosensitivity, pink to dark brown fluorescent urine under Wood’s light (long-wave 





biochemical analysis of porphyrins from biological samples as urine, stool, plasma, or 
red blood cells. Determination of the residual activity of UROS completes the 
diagnosis. Enzymatic methods are implied to analyse isomers I and III formation, which 
are preferentially detected by high-performance liquid chromatography (HPLC). 
 
Figure 9. Symptoms of Congenital Erythropoietic Porphyria. A-C) A severely affected CEP 
patient who had multiple sun-induced skin lesions. The cutaneous bullae and vesicles burst and became 
secondarily infected, leading to bone involvement and resultant loss of facial features and digits. B) 
Note the brownish discolored teeth, which fluoresce (erythrodontia) when exposed to ultraviolet light. 
The erythrodontia is the result of the accumulation of uroporphyrin I and coproporphyrin I in his teeth. 
D) Urine from a CEP patient that fluoresces red under ultraviolet light (left) and from a healthy person 
(right). Adapted from (Balwani and Desnick 2012). 
 
 
Currently, there are no treatments available for CEP. The only curative 
therapies are bone marrow or hematopoietic stem cell transplantation (HSCT). HSCT 
is the most effective treatment to CEP; however, it entails many operative and post-
operative risks and complications for the patients. Oral administration of beta-





in order to prevent skin injuries (Katugampola, Anstey, et al. 2012; Kauffman et al. 
1991; Hogeling et al. 2011; Dupuis-Girod et al. 2005).  
Suppression of erythropoiesis, short or long-term blood transfusions, 
splenectomy in severe cases, and use of agents that help excretion of porphyrins can 
be employed as palliative therapies to alleviate symptomatology. However, these 
treatments show high variability among patients and produce side effects as iron 
overload, thrombocytopenia or infections, among others (Fritsch et al. 1997; Balwani 
and Desnick 2012). 
In view of the current situation, the search for a definitive treatment is urgently 
needed for these patients. In order to better approach therapeutic development, a 
comprehensive analysis of the genetic alterations and their consequences at the 
protein level is required. 
1.3.4 Uroporphyrinogen III Synthase mutations and stability 
The UROS human protein is a monomer of 29.5 kDa encoded by the UROS gene 
(Figure 10). This is located on chromosome 10q25.2-q26.3 and consists of 10 exons 
and 10 introns. UROS gene has two different promoters that generate housekeeping 
and erythroid-specific transcripts (Figure 10). The two transcripts share nine common 
coding exons (2B to 10) but have unique 5'-untranslated sequences (exons 1 and 2A). 
The housekeeping transcript is expressed in all tissues, while the erythroid transcript 
is expresses only in erythropoietic tissues and its activity is increased during hemin-
induced erythroid differentiation. An alternative erythroid-specific promoter is 
present also in the first introns of the genes that encode the second and third enzymes 
in the heme biosynthetic pathway. This suggests a common regulatory mechanism for 
erythropoiesis and erythroid differentiation, which may have evolved from an 
ancestral sequence that could have duplicated and diverged into separate enzymes in 







Figure 10. Schematic representation of UROS gene. Blue boxes indicate common exons, green 
and yellow boxes indicate alternative housekeeping and erythroid 5’ UTRs, respectively. Arrows 




To date, over 49 UROS disease-causing mutations are reported, according with 
the Human Gene Mutation Database (www.hgmd.org), including missense/nonsense 
mutations (29), splicing defects (4), insertions/deletions (10) and mutations in 
regulatory regions (6). Moreover, a gain of function mutation in the ALAS2 gene and 
trans-acting mutation in GATA1 gene (R216W) have also been described as modulator 
or causative of CEP, respectively (Phillips et al. 2007).  
The C73R (c.217 T>C) missense mutation in the exon 4 is the most common 
pathologic allele found in about 40% of the patients and is associated with a severe 
phenotype (Frank et al. 1998). Homozygous patients for this mutation have less than 
1% UROS activity as consequence of a misfolded and unstable protein, which is 
prematurely degraded via the proteasome (Bishop et al. 2006; 2011). Fortian and co-
workers demonstrated that the cysteine in position 73 is not essential for the catalytic 
activity of the enzyme, but its mutation to arginine speeds up the process of 
irreversible unfolding and aggregation. The enzyme itself retains about 50% of normal 
activity but its quick degradation via the UPS dramatically reduces the amount of 
intracellular available enzyme. Moreover, mutant protein levels can be restored upon 





Urquiza and co-worker showed that the off-patent synthetic antimicrobial ciclopirox 
(CPX) acts as an UROS pharmacological chaperone in vitro and in vivo. CPX acted as an 
allosteric chemical stabilizer of UROS and did not affect the enzyme’s catalytic role 
(Urquiza et al. 2018).  
Mouse models of human porphyrias have proven useful to investigate the 
pathogenesis of the diseases and to facilitate the development of new therapeutic 
approaches. To date, mouse models have been generated for all major porphyrias, 
including few different mouse models for CEP. They recapitulate many of the clinical 
and biochemical features of this severe human disease. Moreover, they have been 
particularly useful to study the mechanisms underlying the disease and for preclinical 
evaluation of novel therapeutic approaches. In spite of this, homozygous C73R mouse 
model has poor viability and chronic health issues, posing numerous practical and 
ethical challenges for experimental setups (Bishop et al. 2006). Therefore, it is urgent 
to find new strategies that ensure the generation of viable models. Since presently the 
most promising therapeutic approach for CEP is based on the use of pharmacological 
chaperons, a humanized model could improve drug discovery providing a better 
system for designing and testing highly specific compounds. Additionally, an inducible 
model could partially solve viability and health problems, facilitating experimental 
procedures. 
1.3.5 Genome editing technology: CRISPR/Cas9 
Nowadays, precise targeted gene modification is considered the standard 
procedure to analyse gene function and to generate animal models providing the 
potential for therapeutical applications. During the last few decades, simple and 
economic methods for gene-targeted modification have been engineered, including 
zinc finger nucleases, transcription activator-like effector nucleases and CRISPR 
(Clustered Regularly Interspaced Short Palindromic Repeats)/Cas9 system. These 
nucleases generate a DNA double-strand break (DSB) at the targeted genome locus. 
The break induces the repair response through an error-prone non-homologous end 
joining (NHEJ) or homology-directed repair (HDR). NHEJ is activated in the absence of 





locus. In presence of a donor template with homology to the targeted locus, the HDR 
pathway is activated, allowing precise repair or the generation of specific mutations 
(Ma, Zhang, and Huang 2014). 
The CRISPR/Cas9 system was first described as an adaptive immune system in 
prokaryotes, which use it as a powerful defensive strategy against viral invaders. Now, 
it has been engineered for genome editing. CRISPR genome editing system is based on 
a non-specific endonuclease (Cas9 or the closely related Cpf1) to cut the genome and 
on two RNAs: the 20 nucleotides crRNA (crispr RNA) that defines the genomic target 
for Cas9, and the tracrRNA (trans-activating crispr RNA), which acts as a scaffold linking 
the crRNA to Cas9 (Figure 11). In most of experimental procedures, these two small 
RNAs are condensed into one RNA sequence known as guide RNA (gRNA) or single 
guide RNA (sgRNA). 
 Cas9 and its variants have two endonuclease domains: The N-terminal RuvC-
like nuclease domain and the HNH-like nuclease domain near the centre of the 
protein. Once bound to the target, Cas9 undergoes a conformational change that 
positions the nuclease domains to cleave opposite strands of the target DNA. A 
"nickase” Cas9 mutant, which cuts only one strand of DNA, is commonly used with 
paired gRNAs to lower off-target cuts frequency. gRNA length has also been optimized. 
Truncated gRNAs with <20 base homology shown less off-target activity (Fu et al. 
2014).  
In order to be cut by Cas9, the DNA target must contain a 3-base pair sequence, 
known as the Protospacer Adjacent Motif or PAM, immediately downstream (3’) of 
the site targeted by the guide RNA. Thus, the result of Cas9-mediated DNA cut is a DSB 
within the target DNA ~3-4 nucleotides upstream of the PAM sequence. In the absence 






Figure 11. CRISPR/Cas9 system. tracRNA acts as a scaffold for the crRNA, which guides the 
Cas9 on the target sequence. Cas9 produces DSB ~3-4 nucleotides upstream of PAM sequence. Arrows 
indicate the cutting site.  
 
 
1.3.6 FLEX-Switch System 
The Cre-LoxP system is a common site-specific genetic manipulation tool. This 
system, through a site-specific recombination, allows modulating the expression of 
targeted genes in cell lines and animal models, at a certain developmental stage or in 
specific tissues. Cre recombinase is a tyrosine recombinase enzyme derived from the 
P1 bacteriophage, and is a member of the λ integrase superfamily of SSRs (subtilisin‐
like serine proteases). Cre mediates DNA recombination, involving strand cleavage, 
exchange and ligation, through the recognition of DNA target sites, the 34 bp LoxP 
sites (locus of crossover (x) in P1). Each LoxP site includes two sets of 13 bp recognition 
sequences separated by 8 bp spacer sequence. The 13 bp sequences are palindromic 
while the 8 bp spacer is responsible for the directionality of the Lox site. Different Cre 
recombination outcomes may be generated based on the location and orientation of 





between is reversibly inverted (Figure 12, left panel). However, if two LoxP sites are in 
the same orientation, the sequence in between is excised (Figure 12, middle panel). 
This process is essentially irreversible. A reversible translocation event is generated at 
the LoxP sites when they are located on separate DNA molecules (Figure 12, right 
panel) (Friedel et al. 2011). 
 
Figure 12. The directionality of the Lox sites determines the outcome of the Cre mediated 
recombination. When the two LoxP sites are in the opposite orientations, the sequence in between is 
inverted (left panel). However, if two LoxP sites are in the same orientation, the sequence in between 
is excised (middle panel). A translocation event is generated at the LoxP sites when they are located on 
separate DNA molecules (right panel). Edited from Addgene. 
 
 
Cre-dependent genetic switch (FLEX-Switch) system (Schnütgen et al. 2003) is 
a genetic tool based on the use of two pairs of heterotypic Lox sites, WT (LoxP) and 
mutant (e.g. Lox511). Cre recognizes both Lox variants, but only identical pairs of Lox 
sites can recombine with each other and not with any other variant. By combining the 
ability of Cre recombinase to invert or excise a DNA fragment and the availability of 
both WT and mutant Lox sites, the FLEX-Switch system allows a gene to be turned off, 
while the expression of another one is simultaneously turned on (Figure 13). This site-
specific genetic manipulation can be combined with the CRISPR/Cas9 technology as a 






Figure 13. FLEX-Switch System. Incompatible pairs of Lox sites can be used to induce the 
expression of a gene of interest, simultaneously to the silencing of another gene, in two steps of 
recombination. First, using LoxP (orange arrowheads) or Lox511 (yellow arrowheads) sites, Cre can flip 
the middle sequence inverting the strand sense of the genes. Next, the sequence between two Lox sites 
faced in the same direction is irreversibly excised. 
 
 
Considering the advantages of this technology and the need for a new genome 
editing strategy, the FLEX-Switch system could represent the ideal approach for the 
generation of a new viable humanized inducible CEP C73R mouse model. 
 
1.4 Townes-Brocks Syndrome: a developmental rare disease 
TBS is a rare disease with an estimated prevalence of 1 per 350.000 live births. 
It is an autosomal dominant genetic disorder characterized by three major features: 
imperforate anus, dysplastic ears and thumb malformations such as triphalangeal 
thumbs, duplication of the thumb (preaxial polydactyly) and thumb hypoplasia (Powell 
and Michaelis 1999). TBS is also frequently associated with other minor features such 
as sensorineural and/or conductive hearing impairment, foot malformations, renal 
impairment including end-stage renal disease or polycystic kidneys, together with 





TBS features are schematized in Figure 14. The diagnosis of TBS is established 
by the presence of the three major features. If only two major features are present, 
the minor features and the absence of atypical features further support the diagnosis. 
 
Figure 14. Classical symptoms of Townes‐Brocks Syndrome. A-B) TBS patientes exhibit 
polydactyly in hands. D) Dysplastic ears are a common TBS feature, compared to normal ear in C). E) 
TBS individuals might also exhibit preauricular tags. F) Major, minor and atypical features in TBS. (Powell 
and Michaelis 1999; J. Kohlhase et al. 1998). 
 
 
TBS is caused by mutations in the gene encoding the transcriptional repressor 
SALL1 and is associated with the presence of a truncated protein that localizes to the 
cytoplasm in contrast to the WT protein, which resides primarily in the nucleus (Sato 
et al. 2004). Recently, Bozal-Basterra and co-workers proposed that TBS might be 
considered a ciliopathy, which is a group of diseases caused by malfunction of the 
primary cilia. In agreement with this classification, TBS individuals-derived primary 
fibroblasts show a higher rate of ciliogenesis, abnormally elongated cilia, aberrant cilia 
disassembly, and SHH (Sonic-Hedgehog) signaling defects (Bozal-Basterra et al. 2018).  
TBS is also referred as TBS1 since a TBS2 disease has been described. Unlike 
TBS1 patients, TB2 patients do not have mutations in the SALL1 gene, but in the DACT1 
gene (Webb et al. 2017). Hear defects, as well as imperforate anus and renal defects 





1.4.1 The SALL family of transcription factors 
SALL (Spalt-like) proteins are zinc finger transcription factors characterized by 
the presence of stereotypical pairs of zinc finger domains along the protein, which are 
thought to mediate interactions with DNA via an AT-rich sequence (Netzer et al. 2006). 
The first zinc finger domain (ZF1) corresponds to a single zinc finger C2HC type, 
conserved only in vertebrates; the rest of the domains (ZF2-5) are organized in 
doublets or triplets of C2H2 type zinc fingers, connected by sequences conserved 
throughout evolution. In vertebrates, the N-terminal region of SALL proteins presents 
a conserved 12 amino acid sequence involved in transcriptional repression (Lauberth 
and Rauchman 2006). Another important N-terminal motif is the conserved 
polyglutamine (PolyQ) domain involved in protein dimerization with itself, with other 
SALL family members or with other factors (Sweetman et al. 2003). Finally, the ZF1 
motif, which may mediate protein-protein interactions rather than DNA binding (Laity, 
Lee, and Wright 2001).  
In Drosophila, two paralogs, Salm and Salr, are implicated in the formation of 
the wing via control of cell differentiation in imaginal discs, the trachea, the sensory 
organs and the nervous system (Cantera et al. 2002; J. F. de Celis and Barrio 2000; J. 
F. de Celis and Barrio 2009). In vertebrates, there are four members of the SALL family, 
defined as SALL1-4. SALL family is very important in different aspects of human health, 
since they are associated to hereditary syndromes and are involved in stem cells 
maintenance and cancer as tumor-suppressor factors (Misawa et al. 2018). Figure 15 
shows a schematic representation of the main conserved domains present in SALL 
proteins.  
While mutations in SALL1 cause TBS, mutations in SALL4 cause Okihiro 
Syndrome (Kohlhase et al. 2002), which is characterized by hearing dysfunction, 
external ear malformation, renal abnormalities, atrial septal defects and facial 
asymmetry. Mutations in SALL2 have been identified as responsible for ocular 
coloboma in human and in mice, a congenital defect resulting from failure in the optic 






Figure 15. Schematic representation of the main conserved domains present in SALL 
proteins. Coloured ovals numbered 1 to 5 represent the zinc finger domains from vertebrate and 
Drosophila Sall homologues. White rectangles represent the polyQ regions. The arrow in SALL1 
indicates the SUMOylation site described for this protein. Coloured horizontal bars below each protein 
indicate the SALL-interaction domains with other proteins. Adapted from (J. F. de Celis and Barrio 2009). 
 
 
1.4.2 Truncations of SALL1 cause Townes-Brocks Syndrome 
SALL1 (MIM: 602218) is one of the four members of the SALL family in 
vertebrates. SALL1 is a transcriptional repressor. The N-terminal region of SALL1 
mediates transcriptional repression via the interaction with the nucleosome 
remodelling deacetylase (NuRD) complex through a conserved 12 amino acid 
sequence (Kiefer et al. 2002; Lauberth and Rauchman 2006). Moreover, SALL1 is linked 





More than 50 point-mutations in SALL1 were described that cause premature 
stop codons by frame shifts, short insertions or deletions, mainly in a hot-spot region 
located between the N-terminal part of the protein and the ZF1, as shown in Figure 16  
(Botzenhart et al. 2007; 2005; J. Kohlhase et al. 1998; Borozdin et al. 2006; Nakajo 
et al. 1990). 
 
Figure 16. Schematic representation of SALL1 protein. Schematic representation of the SALL1 
protein and localization of the mutations identified. Zinc fingers are indicated as coloured ovals. The 
red horizontal bar marks the refined hot-spot region and the blue bar assigns the glutamine rich 
domain. Adapted from (Botzenhart et al. 2007). 
 
 
Many SALL1 mutations reported in TBS result in truncated proteins that lack 
most of the zinc finger pairs, but retain the N-terminal domain, the ZF1 and the PolyQ 
region. In fact, truncated proteins causing TBS are still able to form multimers with 
themselves and with full-length SALL proteins (Lauberth et al. 2007; Kiefer et al. 2003). 
The c.826C>T (R267X) mutation in the exon 2 is the most common allele found in TBS 
patients. 
1.4.3 SALL1 SUMOylation 
Post-translation modifications can modulate transcription factors activity 
altering their regulation and localization. In Drosophila, SALL proteins can be 
SUMOylated. SUMOylation alters their nuclear localization and influence the vein 





(Sánchez et al. 2010; 2011). Through human library-based yeast-two-hybrid screen, 
Netzer and co-worker identified UBC9 and SUMO1 as interactors of SALL1 and 
reported the SUMOylation of K1086 in vitro (Netzer et al. 2002). Pirone et al. 
confirmed SUMOylation of SALL1 in cells using the bioSUMO system, a comprehensive 
method for studying SUMOylated proteins. As shown in Figure 17, they showed that 
SALL1 can be modified by both SUMO1 and SUMO3 and that it partially colocalized in 
the nucleus with bioSUMO1, similarly than with the endogenous SUMO2/3 (Pirone 






Figure 17. SALL1 is modified by SUMO1 and SUMO2/3 in mammalian cells. A) Western blot 
of HEK 293FT cells showing that the transcription factor SALL1 fused to YFP was SUMOylated in 
presence (+) of bioSUMO1 (lane 4) or bioSUMO3 (lane 5; bioSUMO1-BirA or bioSUMO3-BirA, 
respectively). Black arrowhead indicates the modified SALL1-YFP in the elution panel (lanes 4, 5), which 
is shifted in comparison to the non-modified SALL1-YFP in the input panel (white arrowhead, lanes 1–
3). Molecular weight markers are shown to the left. B-C) Partial colocalization between SALL1-YFP (B, 
green) and bioSUMO1 (purple) (bioSUMO1-BirA-UBC9) in U2OS cells (B) or with endogenous SUMO2/3 
(C, purple). White arrowheads indicate colocalization. Nuclei were stained with DAPI (blue). B’-C”) 




For a deeper analysis of SALL1 SUMOylation, our laboratory generated a SALL1 
mutant SUMO unable to undergo SUMOylation (Pirone 2016). By analyzing the full-
length amino acidic sequence of SALL1 by the SUMOplot program 
(http://www.abgent.com/sumoplot), 7 possible SUMO consensus sites were found 
with a high probability score. Four high score sequences were selected and mutated 
by substituting each lysine (K571, K592, K982 and K1086) with an arginine (SALL1-4KR) 
(Figure 18). The SALL1-4KR mutant lost the capacity to be SUMOylated in cells, 






Figure 18. Schematic representation of identified and mutated SUMO consensus sites in 
SALL1. Ovals represent the zinc fingers distributed along the protein. Q represents the poly-glutamine 
domain. In red, SUMO consensus sites mutated in SALL1ΔSUMO. 
 
 
Interestingly, recent mass spectrometry experiments to find SUMOylated 
proteins in different cellular conditions, revealed that all the SALL human homologues 
can be SUMOylated (Hendriks and Vertegaal 2016a; 2016b). In the case of SALL1, 
various SUMOylation sites have been detected by mass spectrometry, corresponding 
to the consensus sites identified previously, the most prominent site being the K1086 
previously identified (Netzer et al. 2002). 
1.4.4 SALL1 Interactors 
In order to gain insights on SALL1 function in the context of TBS, “proximity 
proteomics” BioID methodology in combination with Mass Spectrometry was used to 
identify possible interactors of human SALL1 (schematized in Figure 19) (Bozal-






Figure 19. Search of SALL1 interactors by proximity proteomics. Schematic representation of 
the BioID methodology in combination with Mass Spectrometry (Bozal-Basterra et al. 2018). Adapted 
from (Roux et al. 2012). 
 
 
Gene Ontology (GO) analysis revealed that many of the putative interactors of 
SALL1 were nuclear proteins, most them factors involved in gene expression 
regulation. Interestingly, SALL1 interacted with many components of the UbL 
pathway, including E1, E2 and E3 enzymes. Among other categories, the SUMO ligase 
term was well represented in the list of interacting factors (Figure 20). The known 
mammalian SUMO E3 ligases CBX4, PIAS1, PIAS2 and PIAS4 were identified as putative 
SALL1 interactors, opening the possibility that one of those ligases was involved in the 
SUMOylation of SALL1. Interestingly, the genetic interaction between Drosophila sall 
genes and Polycomb (Pc), the Drosophila homolog of CBX4, was previously reported 
since mutations in salm enhanced the phenotype of Pc group mutations during 
embryogenesis (Casanova 1989; Landecker, Sinclair, and Brock 1994). However, the 
mechanisms underlying the interaction between CBX4 and SALL1 in human were still 





CBX4 opened an opportunity of research with the aim to better understand the 
implications of SALL1 SUMOylation in gene regulation. 
 
Figure 20. Analysis of SALL1 interactors by Mass Spectrometry. GO analysis for biological 







1.4.5 CBX4 is a member of the Polycomb group 
The Polycomb group of proteins (PcG) is a conserved family of transcriptional 
repressors involved in epigenetic silencing and in the maintenance of cell identity 
during development. They regulate the expression of numerous genes that participate 
in different cellular processes including cell fate choices and cell cycle control. 
PcG proteins assemble into chromatin-associated multiprotein complexes 
known as Polycomb Repressive Complex 1 (PRC1) and Polycomb Repressive Complex 
2 (PRC2), containing enzymatic subunits to modify histones (Bracken and Helin 2009; 
Simon and Kingston 2009; Entrevan, Schuettengruber, and Cavalli 2016). PRC2 
complex is composed by the core components EED (Embryonic ectoderm 
development), SUZ12 (Suppressor of zeste 12) and EZH2 (Enhancer of zeste 2), which 
mediate the trimethylation of histone H3 at lysine 27 (H3K27me3), a landmark for 
gene transcriptional repression. The canonical PRC1 complex (cPRC1) is composed of 
CBX (Chromobox), PCGF (Polycomb group ring finger), RING (Ring finger protein), and 
PHC (Polyhomeotic-like) proteins. CBX proteins in PRC1 (CBX2,4,6,8) recognize and 
bind the Histone H3 trimethylated at lysine K27 (H3K27me3) facilitating the 
recruitment of cPRC1 to PRC2-target genes. RING1A/B proteins in the cPRC1 complex, 
together with PCGF2/4 proteins, can then catalyse the monoubiquitylation of histone 
H2A at lysine 119 (H2AK119ub1), which contribute to chromatin compaction and 
repression of lineage-specific genes (Figure 21) (Eskeland et al. 2010; Aranda, Mas, 







Figure 21. Chromatin silencing marks by PRC1 and PRC2. PRC2, through the catalytic subunit 
EZH2, promotes the trimethylation (me3) of lysine 27 (K27) of the histone H3, which is then recognized 
by the CBX protein of the cPRC1. Next, the RING1 subunit of PRC1 catalyses the ubiquitination (Ub) of 
the lysine 119 (K119) of the histone H2A. 
 
 
However, this hierarchical model of PRC2-dependent H2AK119 ubiquitination 
has been challenged in recent years by the identification of non-canonical PRC1 (nc-
PRC1) complexes, which do not require PRC2 activity to mediate H2AK119ub1 and in 
which the CBX component is replaced by RYBP (RING1 and YY1 binding protein) or 
YAF2 (YY1 associated factor) (Gao et al. 2012; Morey et al. 2013; Zhao et al. 2020).  
PcG proteins regulate chromatin structure at multiple levels, from the linear 
genome by modifying histones by binding Pc Regulatory Elements (PRE) in target 
genes, to organizing topologically associating domains (TADs) in the nuclear space. 
TADs represent linear units of chromatin that fold as 3D structures and may establish 
dynamic long-range interactions with each other, mostly due to the dispersed 
genomic distribution of the target sites, to form Pc nuclear bodies (Figure 22) 






Figure 22. Pc bodies result from several engaged silenced-chromatin regions. Binding of PcG 
proteins to chromatin can induce DNA compaction and PcG proteins are involved in mediating looping 
interactions between cis-regulatory elements like enhancers and promoters. Linear chromatin regions 
can fold into specific 3D structures to form TADs. In addition, Polycomb-repressed TADs show long-
range interactions with each other mediated by PcG proteins. PcG proteins accumulate in the nucleus 
to form PcG foci, which are the nuclear counterparts of genomic domains, silenced by PcG proteins and 
may contain individual PcG TADs or multiple TADs engaged in long-range interactions. Adapted from 







PcG genes were originally identified as factor mediating repression of 
homeotic genes. Hox (homeobox) genes are grouped in genomic clusters and encode 
transcription factors defining cellular identities along the major and secondary body 
axes. In human there are 39 Hox genes organized in four clusters on four different 
chromosomes: HoxA, HoxB, HoxC and HoxD (Figure 23). During development, collinear 
regulation of Hox genes in space and time is critical for patterning the body plans of 
many animals with bilateral symmetry. Dynamic patterns of histone marks and higher-
order chromatin structure are important determinants of Hox gene regulation 
(Deschamps and Duboule 2017; Soshnikova 2014).  
 
Figure 23. Clustering of Hox genes in mammals. In mammals there are 39 Hox genes organized 
in four clusters HoxA, HoxB, HoxC and HoxD. Hox genes are indicated by coloured boxes. Different 
colours indicate gene that share a common ancestor.   
 
 
In addition to Hox genes, PcG complexes also occupy promoters of members 
of other transcription factor families, such as GATA family, that have key roles in a 
variety of developmental processes. Members of the GATA4, 5 and 6 subfamily are 
expressed in various mesoderm- and endoderm-derived tissues, where they play 
critical roles in regulating tissue-specific gene expression controlling the development 
and function of different cell types [(Aronson, Stapleton, and Krasinski 2014; 
Katsumura 2017; Boyer et al. 2006).  
Different CBX proteins share the N-terminal chromodomain and a small 
hydrophobic region at the extreme C-terminal called C-box. However, among CBX 





colleagues demonstrated that CBX4 is a SUMO E3 ligase for the transcriptional 
corepressor CtBP (carboxyl-terminus binding protein) and is itself SUMOylated. 
Several CBX4 SUMOylation targets have been described (Kagey, Melhuish, and 
Wotton 2003; Chen et al. 2018; J. Li et al. 2014; Ismail et al. 2012; B. Li et al. 2007).  
Two SIMs have been identified in CBX4, which are required for the SUMO E3 
ligase activity, together with the chromodomain and the C-box. Schematized 
representation of some important CBX4 domains is shown in Figure 24. The 
chromodomain of CBX4 is also necessary for the efficient binding to H3K27me3, as 
well as its SUMOylation. In fact, Kang and colleagues demonstrated that CBX4 is a 
target of the SUMO protease SENP2 and that SUMOylation is essential for CBX4-
mediated PRC1 recruitment to H3K27me3. In SENP2 null mutant embryos, 
SUMOylated CBX4 accumulates and CBX4 occupancy on the promoters of PcG target 
genes is markedly increased with consequent increment of targets repression (Wotton 
and Merrill 2007; Merrill et al. 2010; Kang et al. 2010). Interestingly, a critical role for 
SUMOylation in the regulation of PcG target gene expression was previously reported 
in Drosophila. There, Pc SUMOylation was shown to regulate PcG-mediated silencing 
by modulating the kinetics of Pc binding to chromatin, as well as its ability to form 
Polycomb bodies (Gonzalez et al. 2014). 
 
Figure 24. Schematic representation of CBX4 important motifs and domains. Some important 








Transcriptional repression and SUMO E3 ligase activities endows CBX4 with a 
key role in several essential pathways. CBX4 has been described to facilitate the 
differentiation of hematopoietic stem cells (Klauke et al. 2013), counteracting cellular 
senescence (Ren et al. 2019) and maintaining the epithelial lineage identity via 
repression of non-epidermal lineage and cell cycle inhibitor genes (Mardaryev et al. 
2016). Moreover, CBX4 is known to be recruited rapidly to DNA damage (Ismail et al. 
2012) and has emerged as a critical component of the DNA end resection machinery 
(Soria-Bretones et al. 2017). Finally, CBX4 plays an important role in the occurrence 
and development of tumours. In fact, dysregulation of CBX4 contributes to the 
progression of human cancers in which it can acts as both oncogene and tumour 
suppressor, depending on the cellular context (Wang et al. 2016). 
 
Given the importance of SALL1 and CBX4 in gene regulation during 
development and their possible interaction in the cells, to understand the relationship 
between these two transcription factors might help to clarify their role in cellular 


































Materials and Methods 
Cell culture 
Mouse NIH3T3-Shh-LIGHT2-Cas9-blast (Taipale et al. 2000), human U2OS 
(ATCC HTB-96) and HEK 293FT (Invitrogen) cells, as well as derived cell lines, were 
cultured at 37oC with 5% of CO2 in DMEM (Dulbecco’s modified Eagle’s medium; 
Gibco) supplemented with 10% FBS and 1% penicillin/streptomycin (GIBCO). 
Cell Transfection 
HEK 293FT cells were transiently transfected using calcium phosphate in 10 cm 
dishes with 10 μg of DNA using different sets of plasmids according to each 
experiment.  
U2OS cells were transiently transfected using Effectene®( QIAGEN) according 
to the manufacturers datasheet. 
CRISPR/Cas9 genome editing 
The mouse Uros locus was targeted in NIH3T3-based Shh-LIGHT2 fibroblasts 
[(Taipale et al. 2000); kind gift from A. McGee, Imperial College]. Cas9 was introduced 
into Shh-LIGHT2 cells by lentiviral transduction (Lenti-Cas9-blast; Addgene #52962; 
kind gift from F. Zhang, MIT) and selected with blasticidin (5 µg/ml). Two high-scoring 
sgRNAs were selected (http://crispor.tefor.net/) to target near the second exon of 
Uros gene (Table 1). To express both sgRNAs and additional Cas9 with puromycin 
selection, these sequences were cloned into px459 2.0 (Addgene #62988; kind gift of 
F. Zhang, MIT).  
Transfections were performed in NIH3T3-based Shh-LIGHT2_Cas9-blast cells 
with Lipofectamine 3000 (Thermo). 2 µg of CondMmUROSv6_puro_Cre-ERT2 plasmid 
were transfected into the cells together with 0.67 µg of each sgRNA. Cells were treated 
with 10 µM of RS1 (Sigma) 16 hours after the transfection. 24 hours after transfection, 
transient puromycin selection (1 µg/ml) was applied for 48 hours to enrich for 
transfected cells. Cells were plated at clonal density, and well-isolated clones were 
picked and propagated individually. Western blotting was used to identify clones 





Materials and Methods 
Table 1. Relevant sequences. 
Name Sequence 
T2A (GSG) E G R G S L L T C G D V E E N P G P 













sgRNA1 CTTACTAAAAGACGCCA_AGG  
sgRNA2 CACAATCGCAGCTCCTG_CAA 
(*) hUROSopt: cDNA sequence (exons 3-10) of human UROS optimized for mouse codon usage. 
 
Cycloheximide assay 
3 x 105 HEK 293FT cells per well were plated in 6-well plates. Four hours later, 
cells were transfected with 2 µg of CMV-SALL1-YPF, CMV-SALL1ΔSUMO-YFP or CMV-
GFP--Galactosidase plasmid per well using the calcium phosphate method. Cells 
were treated with 50 µg of cycloheximide (CHX) in combination or not with 10 µM of 
MG132 at different time points (0h, 4h, 8h or 16h). Cells were lysed in RIPA buffer [150 
mM NaCl, 1.0% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris, pH 8.0, 
protease inhibitors (Roche)] and analyzed by Western blot. 
Fluorescence-activated cell sorting  
Live cells were collected in 1x PBS (phosphate buffered saline) and flow 
cytometry analyses were performed using the BD FACSCantoTM II system (BD 
Biosciences). Data were analyzed using the FlowJo software. Porphyrin fluorescence 




Materials and Methods 
Generation of vectors 
The following vectors were used in this study (Table 2). All constructs for this 
work were done by Dr. J. D. Sutherland and the candidate, unless otherwise specified. 
DNA fragments were amplified from the indicated plasmids by high-fidelity PCR 
Platinum SuperFi (Thermo) and, when required, digested using the indicated 
restriction enzymes (Fermentas; NEB). PCR products were purified using mi-Gel 
Extraction kit (Metabion) and afterwards ligation was performed using Gibson 
Assembly Master Mix (BioLabs). All vectors were checked by sequencing. 
Table 2. Vectors used in the study 
Name of the vectors Reference Cloning sites/notes 
pCAG-ERT2CreERT2 Addgene #13777 Mlu I - Spe I 
17ABAVMP_CondMmUROSv6_pMA This work/GeneArt Mlu I - Spe I 
A (CondMmUROSv6_ERT2-Cre-ERT2) This work Mlu I - Spe I 
B (CondMmUROSv6_Cre-ERT2) This work Mlu I - Spe I ; BsiW I - Asc 
I 
C (CondMmUROSv6_puro_Cre-ERT2) This work Mlu I - Spe I 
CMV-CBX4-YFP J.D.Sutherland, unpublished - 
CMV-SALL1-YFP (Pirone et al. 2017) - 
CMV-SALL1ΔSUMO-YFP J.D.Sutherland, unpublished - 
CMV-SALL1ΔSIM-YFP J.D.Sutherland, unpublished - 
CMV-YFP (Pirone et al. 2017) - 
CMV-SALL1-2xHA J.D.Sutherland, unpublished - 
CMV-SALL1-826-2xHA J.D.Sutherland, unpublished - 
CB6-HA  (Pirone et al. 2017) - 
CB6-SALL1-HA J.D.Sutherland, unpublished  
CB6-SALL1ΔSUMO-HA J.D.Sutherland, unpublished - 
CB6-CBX4-HA J.D.Sutherland, unpublished  - 
CMV-GFP-β-Galactosidase J.D.Sutherland, unpublished  - 
CMV-BirA-2A-puro J.D.Sutherland, unpublished  - 
CMV-BirA-2A-bioUb-puro J.D.Sutherland, unpublished  - 
px459 2.0  Addgene #62988 - 
Lenti-Cas9-blast vector  Addgene #52962 - 





Materials and Methods 
Genotyping and PCR primers 
The following primers were used in this study (Table 3). Primers were used for 
either Sanger sequencing or PCR amplification of the vectors. 
Table 3. Genotyping and PCR oligonucleotide sequences. 












































































huUROS_post-flip 1.rev 5’-GCAAGCTTTTCTGCATTTCC-3’ 





























All steps were performed at 4oC. HEK 293FT cells were transfected using the 
calcium phosphate method with different combinations of plasmids and collected 
after 48 hours. Cells were washed 3 times with 1x PBS and lysed in 1 ml of lysis buffer 
[25 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% NP-40, 0.5% Triton X-100, 5% 
glycerol, protease inhibitors (Roche)]. Lysates were sonicated and spun down at 25000 
x g for 20 minutes. After saving 40 μl of supernatant (input), the rest of the lysate was 
incubated overnight with 30 μl of pre-washed GFP-Trap resin (Chromotek) in a 
rotating wheel. Beads were washed 5 times for 5 minutes each with washing buffer 
(WB) (25 mM Tris-HCl pH 7.5, 300 mM NaCl, 1 mM EDTA, 1% NP-40, 0.5% Triton X-
100, 5% glycerol). Beads were centrifuged at 2000 x g for 2 minutes after each wash. 
For elution, samples were boiled for 5 minutes at 95oC in 2x Laemmli buffer. 
Transfected plasmids: CMV-CBX4-YFP, CMV-SALL1-YFP, CMV-SALL1ΔSUMO-
YFP, CMV-SALL1ΔSIM-YFP, CMV-YFP, CMV-SALL1-2xHA, CMV-SALL1-826-2xHA, CB6-
HA, CB6-SALL1-HA, CB6-SALL1ΔSUMO-HA, CB6-CBX4-HA. 5 µg of each plasmid were 




Materials and Methods 
GST-SUMO proteins purification 
GST fusion proteins were produced from 200 ml of E. coli C41DE3PLYS cells 
grown in a rich medium. A standard induction protocol was used, shifting log-phase 
cultures (A600= about 0.6) from 37oC RT (room temperature); saved non-induced cells 
and added IPTG to a final concentration of 1 mM overnight at 20oC with constant 
vigorous shaking. Bacteria were recovered and centrifuged at top speed at 4oC for 15 
minutes. Cells were lysed in lysis buffer [1mM PFMS in EtOH, lysozyme 1mg/ml, 1x 
protease inhibitors (Roche) in 1x PBS], sonicated and centrifuged at 4oC 20000 x g, 20 
minutes. Supernatants were collected and passed through GST columns. GST-fused 
proteins were purified by dialysis. The amount of purified proteins was quantified by 
BCA kit (Thermo Fisher Scientific), checked by PAGE, and stained by Coomassie.  
GST-Pulldown 
All steps were performed at 4oC. 100 µl of GST-fused SUMO proteins were 
incubated at 4oC overnight with 300 µl of glutathione-sepharose beads pre-
equilibrated in lysis buffer[25 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% NP-
40, 0.5% Triton X-100, 5% glycerol, protease inhibitors (Roche)]. Next, beads were 
centrifuged 2 minutes at 2000 x g and washed four times with WB (25 mM Tris-HCl pH 
7.5, 300 mM NaCl, 1 mM EDTA, 1% NP-40, 0.5% Triton X-100, 5% glycerol).  
HEK 293FT cells were transfected using the calcium phosphate method with 
different combination of plasmids and collected after 48 hours. Cells were washed 3 
times with 1x PBS and lysed in 1 ml of lysis buffer. Lysates were sonicated and spun 
down at 25000 x g for 20 minutes. After saving 40 μl of supernatant (input), the rest 
of the lysate was incubated overnight with 30 μl of GST-SUMO beads in a rotating 
wheel. Beads were washed 5 times for 5 minutes each with WB (25 mM Tris-HCl pH 
7.5, 300 mM NaCl, 1 mM EDTA, 1% NP-40, 0.5% Triton X-100, 5% glycerol). Beads were 
centrifuged at 2000 x g for 2 minutes after each wash. For elution, samples were boiled 
for 5 minutes at 95oC in 2x Laemmli buffer. 
High-performance liquid chromatograph analysis  
A high-performance liquid chromatograph (Shimadzu) with an autosampler 




Materials and Methods 
C18 (250 x 3 mm; 5 μm particle size) purchased from Thermo Scientific. The method 
to separate the porphyrins was facilitated by 60 minutes gradient elution and a two-
component mobile phase consisting of ammonium acetate (1 M, pH 5.16) filtered 
through 0.1 μm as solvent A and 100% acetonitrile as solvent B. Gradient elution 
commenced upon injection at 0% B, increased to 65% B for 30 minutes, remained for 
5 minutes, returned to 0% B in 15 minutes and remained for 10 minutes in order to 
re-equilibrate the column at 0% B before the next injection. The flow rate was 1 ml 
min-1 and the sample injection volume was 100 µl. All analyses were performed at 
20oC and the spectra were taken at an excitation wavelength of 405 nm and an 
emission wavelength of 610 nm. The concentrations of porphyrins were calculated 
with five-point calibration curve ranging from 0.0 to 100 pM. This protocol was 
performed in collaboration with Dr. Pedro Urquiza and Itxaso San Juan Quintana from 
the Precision Medicine and Metabolism Lab at CIC bioGUNE.  
Immunoprecipitation 
All steps were performed at 4oC. Cells were collected 24 hours after seeding, 
washed 3 times with 1x PBS and lysed in 1 ml of lysis buffer [20 mM Tris-HCl pH 7.5, 
137 mM NaCl, 2 mM EDTA, 1% NP-40, 5% glycerol, protease inhibitor mixture (Roche)]. 
Lysates were incubated overnight with 1 µg of anti-Creantibody (Cell Signalling) and 
for additional 4 hours with 40 μl of pre-washed Protein G Sepharose 4 Fast Flow beads 
(GE Healthcare) in a rotating wheel. Beads were washed 5 times for 5 minutes each 
with WB (10 mM Tris-HCl pH 7.5, 137 mM NaCl, 1 mM EDTA, 1% Triton X-100). Beads 
were centrifuged at 2000 x g for 2 minutes after each wash. For elution, samples were 
boiled for 5 minutes at 95oC in 2x Laemmli buffer. 
Immunostaining 
HEK 293FT_TripZ-SALL1-2xHA and U2OS cells were seeded on 11 mm 
coverslips (50000 cells per well in a 24 well-plate). After washing 3 times with cold 1x 
PBS, cells were fixed with 4% PFA (paraformaldehyde) supplemented with 0.1% Triton 
X-100 in PBS for 20 minutes at RT. Then, coverslips were washed 3 times with 1x PBS. 
Blocking was performed for 20 minutes at RT in blocking buffer (1% BSA, 0.3% Triton 




Materials and Methods 
cells were washed with 1x PBS 3 times. To label Pc bodies we used the primary human 
antibody against CBX4 (Proteintech, 1:100). Donkey anti-rabbit secondary antibodies 
(Jackson Immunoresearch) conjugated to Alexa 568 (1:200) was incubated for 1 hour 
at 37oC. Endogenous SALL1 or SALL1-2xHA in HEK 293FT_TripZ-SALL1-2xHA cells were 
recognized by a primary antibody against SALL1 (R&D, 1:100) and a donkey anti-mouse 
secondary antibodies (Jackson Immunoresearch) conjugated to Alexa 488 (1:200). 
Nuclei were stained with DAPI (10 minutes, 300 ng/ml in 1x PBS; Sigma). Fluorescence 
imaging was performed using a confocal microscope (Leica SP8) with 63x objective, 
zoom 4x. Pc bodies were analyzed using the Fiji software. 
Lentiviral transduction 
Lentiviral expression constructs were packaged using psPAX2 and pVSVG 
(Addgene) in HEK 293FT cells, and lentiviral supernatants were used to transduce HEK 
293FT cells to generate the TripZ-SALL1-2xHA-puro line (using the TRIPZ Inducible 
Lentiviral shRNA [Horizon Discovery]) and GFS-SALL1-blast line (using the Lenti-Cas9-
blast vector [Addgene #52962]). Stable-expressing populations were selected using 
puromycin (1 µg/ml) or blasticidin (5 µg/ml). Lentiviral supernatants were 
concentrated 100 fold before use (Lenti-X concentrator, Clontech).  
Porphyrins extraction  
Cells were lysed in 300 µl of 6 M HCl, sonicated 3 cycles of 25 seconds each and 
incubated at 37oC for 30 minutes in a thermoblock. The samples were then centrifuged 
for 10 minutes at 10000 g. Afterwards, pellets were removed and the supernatants 
were transferred to a fresh filter cellulose acetate membrane centrifuge tube, pore 
size 0.22 μm (Corning® Costar® Spin-X®) and centrifuged for 10 minutes at 4000 g. 
Samples were then analyzed by HPLC. The porphyrins standards were obtained from 
Frontier Scientific Europe (Carnforth, UK), including a chromatographic market kit 
containing the number I isomers of 8, 7, 6, 5, 4 carboxylate porphyrins and 




Materials and Methods 
Proliferation assay 
12 × 103 parental NIH3T3-Shh-LIGHT2-Cas9-blast or CRISPR_UROS cells were 
plated in triplicate in 12-well dishes. 24 hours later, the cells were considered day 0 
and were fixed in formalin 10% for 15 minutes. The same procedure was performed 
after 2 and 4 days. Cell proliferation was measured by staining with crystal violet (0.1% 
in 20% methanol) for 45 minutes at RT. After washing 3 times with water, all samples 
were air dried. The precipitate was solubilized in 10% acetic acid for 20 minutes at RT 
and the absorbance was measured at 595 nm. For each time point, 3 biological 
replicates were measured. 
Quantitative reverse transcriptional PCR analysis 
HEK 293FT cells transfected with 5 µg of CMV-SALL1-YPF, CMV-SALL1ΔSUMO-
YFP or CMV-GFP--Galactosidase plasmids, or HEK 293-TripZ-SALL1-2xHA_puro cells 
induced with different concentrations of doxycycline, were used for qPCR analysis. 48 
hours after transfection or 72 hours after induction, total RNA was obtained by using 
EZNA Total RNA Kit (Omega) and quantified by Nanodrop spectrophotometer. cDNAs 
were prepared using the SuperScript III First-Strand Synthesis System (Invitrogen) in 
20 µl volume per reaction. qPCR was done using PerfeCTa SYBR Green SuperMix Low 
Rox (Quantabio). Reactions were performed in 20 µl, adding 5 µl of cDNA and 0.5 µl 
of each primer (10 µM), in a CFX96 thermocycler (BioRad) using the following protocol: 
95oC for 5 minutes and 40 cycles of 95oC for 15 seconds, 56oC or 62oC for 30 seconds 
and 72oC 20 seconds. Melting curve analysis was performed for each pair of primers 
between 65oC and 95oC, with 0.5oC temperature increments every 5 seconds. Relative 
gene expression data were analyzed using the ΔΔCt method. Reactions were done in 
duplicates and results were derived from at least three independent experiments 
normalized to GAPDH and presented as relative expression levels. Primer sequences 
are reported in Table 4. 
 
































3 x 106 HEK 293FT cells were plated per condition to be analyzed. Four hours 
later, cells were transfected with specific plasmid combinations using the calcium 
phosphate method. 5 µg of each plasmid were used for a 100 mm dish transfection. 
Transfected plasmids: CMV-SALL1-YPF, CMV-SALL1ΔSUMO-YFP, CMV-GFP--
Galactosidase, CMV-BirA-2A-puro, CMV-BirA-2A-bioUb-puro, CB6-CBX4-HA. 16 hours 
after transfection, medium was supplemented with biotin at 50 μM, and 24 hours 
after transfection some plates were treated with 10 μM of MG132 overnight. Cells 
were collected 48 hours after seeded, washed 3 times with 1x PBS and scraped in lysis 




Materials and Methods 
100 mm dish]. Samples were sonicated and cleared by centrifugation at room 
temperature (RT). Cell lysates were incubated overnight with 30 µl of equilibrated 
NeutrAvidin-agarose beads (Thermo Scientific). Beads were subjected to stringent 
washes using the following washing buffers all prepared in 1x PBS: WB1 (8 M urea, 
0.25% SDS); WB2 (6 M Guanidine-HCl); WB3 (6.4 M urea, 1 M NaCl, 0.2% SDS), WB4 
(4 M urea, 1 M NaCl, 10% isopropanol, 10% ethanol and 0.2% SDS); WB5 (8 M urea, 
1% SDS); and WB6 (2% SDS). For elution of biotinylated proteins, beads were heated 
at 99°C in 50 µl of Elution Buffer (4x Laemmli buffer, 100 mM DTT). Beads were 
separated by centrifugation (18000 x g, 5 minutes). Samples were used for Western 
blot analysis. 
Western blot 
Cells were lysed in cold RIPA buffer [150 mM NaCl, 1.0% NP-40, 0.5% sodium 
deoxycholate, 0.1% SDS, 50 mM Tris, pH 8.0, protease inhibitors (Roche)] or assay 
specific lysis buffers. RIPA lysates were kept on ice for 30 minutes vortexing every 5 
minutes and then cleared by centrifugation (25000 x g, 20 minutes, 4oC). Supernatants 
were collected and mixed with Laemmli buffer 5X.  
After SDS-PAGE and transfer to nitrocellulose, membranes were blocked in 1x 
PBS with 5% milk and 0.1% Tween-20. In general, primary antibodies were incubated 
overnight at 4oC and secondary antibodies for 1 hour at RT. Antibodies used: UROS A-
8 (Santa Cruz, 1:1000) detecting mouse protein, UROS G-9 (Santa Cruz, 1:1000) 
detecting human protein, HA (Sigma, 1:1000/1:500), Cre (Cell Signaling, 1:1000), β-
Actin (Sigma, 1:1000), α-Actin (Proteintech 1:100), GFP (Roche, 1:1000), GAPDH 
(Proteintech, 1:1000), SALL1 (R&D, 1:1000), CBX4 (Proteintech, 1:1000), Avitag 
(GeneScript, 1:1000), BirA (Sino Biological Inc., 1:1000), GST (Sigma, 1:1000), Myc (Cell 
Signaling, 1:1000), Vinculin (Cell Signaling, 1:1000). 
HRP-conjugated secondary anti-mouse or anti-rabbit antibodies (Jackson 
Immunoresearch, 1:5000) were used. Proteins were detected using Clarity ECL 
(BioRad) or Super Signal West Femto (Pierce). Quantification of bands was performed 
using Fiji software and normalized against Actin, GAPDH or Vinculin levels, unless 




Materials and Methods 
Statistical analysis 
Statistical analysis was performed using GraphPad 7.0 software. Data were 
analyzed by Shapiro-Wilk normality test and Levene´s test of variance. We used Mann 
Whitney-U test or Unpaired T-test for comparing two groups, One-way ANOVA for 
more than two groups and Two-way ANOVA for comparing more than one variable in 
more than two groups. P values were represented by asterisks as follows: (*) P-value 
< 0.05; (**) P-value < 0.01; (***) P-value < 0.001; (****) P-value < 0.0001. Differences 






























































A previous search for human SALL1 interactors by proximity proteomics followed 
by MS and GO analysis, revealed the E3 SUMO ligase CBX4 as a possible interactor of 
SALL1. Given the nature of both factors, we hypothesized that SALL1 interaction with 







Our general objective was to elucidate the mechanisms behind the relationship 
between SALL1 and the SUMO E3 ligase CBX4 and its biological consequences.  
 
We defined the following specific objectives: 
 
1. To validate and characterize the interaction between SALL1 and CBX4. 
 
2. To analyze the role of SALL1 SUMOylation in the interaction with CBX4. 
 








Post-translation modifications can modulate the activity of transcription factors 
by altering their regulation, localization and interaction with other proteins. As 
mentioned in the introduction, a previous search for human SALL1 interactors by 
proximity proteomics followed by MS and GO analysis, revealed that SALL1 interacted 
with several SUMO E3 ligases, including PIAS1, PIAS2, PIAS4, RANBP2 and CBX4 (Bozal-
Basterra et al. 2018). The E3 SUMO ligase CBX4 was chosen for further investigation, 
since the genetic interaction between the Drosophila sall genes and Pc, the CBX4 
homolog, has been previously described to be important during embryogenesis 
(Casanova 1989; Landecker, Sinclair, and Brock 1994).  
 
4.3.1 Validation of the interaction between SALL1 and CBX4 
SALL1 and CBX4 interact with each other at the protein level 
In order to confirm the interaction between SALL1 and CBX4, we performed a 
pulldown experiment using GFP-Trap agarose beads (Chromotek). GFP-Trap is an affinity 
resin for immunoprecipitation of GFP-fusion proteins and consists of GFP nanobodies 
coupled to agarose beads. CB6-SALL1-HA and CMV-CBX4-YFP plasmids were transiently 
overexpressed in HEK 293FT cells and pulled down using GFP-Trap beads. The results 
were analyzed by Western blot. As shown in Figure 38, SALL1 is detectable in the elution 
when co-transfected with CMV-CBX4-YFP (lane 2) but not when co-transfected with the 
empty vector CMV-YFP (lane 1). These results confirmed the interaction between SALL1 







Figure 38. SALL1 and CBX4 interact with each other at the protein level. Western blot showing 
the expression of CB6-SALL1-HA transfected in HEK 293FT cells together with CMV-CBX4-YFP or CMV-YFP 
alone. CMV-HA empty vector was used as control. Both proteins were pulled down using GFP beads and 
analyzed by Western blot. As shown in the second lane of the pulldown (Elution), CBX4 interacts with 
SALL1. Molecular weight markers are shown to the right. Antibodies were used as indicated to the left. 
EV: empty vector. 
 
 
Truncated SALL1-826C>T interacts with CBX4 
In most of the reported TBS cases, SALL1 presents a mutation in a hot spot region, 
which results in the expression of a truncated protein. The 826C>T mutation (henceforth 
referred to as SALL1-826) is the most common allele found in TBS patients (Botzenhart 
et al. 2007). This mutation generates a truncated protein, which lacks most of the zinc 
finger pairs, but retains the N-terminal domain, including the ZF1, and the PolyQ region 
(Figure 39). In fact, truncated proteins causing TBS are still able to form dimers with 
themselves, with full-length SALL1 or with other SALL proteins. Truncated forms of SALL1 








Figure 39. Schematic representation of SALL1 WT and the SALL1-826C>T mutant. This mutation 
generates a truncated protein that lacks most of the zinc finger pairs, but retains the N-terminal domain 
of SALL1, including the ZF1 and the PolyQ regions. Ovals represent the zinc fingers (ZF) distributed along 
the protein. Q represents the poly-glutamine domain. 
 
 
In order to analyze whether the truncated SALL1-826 mutant preserved the 
capacity of interaction with CBX4 we performed a GFP-Trap pulldown. CMV-SALL1-2xHA 
or the mutant CMV-SALL1-826-2xHA were transiently overexpressed in HEK 293FT cells 
in combination with CMV-CBX4-YFP or CMV-YFP alone. CMV-SALL1-YFP was used as a 
positive control, since it was known to bind to the truncated mutant. GAPDH was used 
as loading control. Our results showed that SALL1-826 mutant was able to interact with 
CBX4. This result suggested that the domain(s) of interaction between SALL1 and CBX4 







Figure 40. SALL1-826 interacts with CBX4. Western blot analysis of SALL1 full-length and 
truncated SALL1-826 fused with HA-tag, transfected in HEK 293FT cells together with CBX4 fused with YFP 
and pulled down using GFP beads. As shown in the lane 2 of the elution panel, SALL1-826 is able to bind 
CBX4. SALL1-826 dimerization with full-length SALL1 was used as positive control. Molecular weight 
markers are shown to the right. Antibodies were used as indicated to the left. 
 
 
4.3.2 Analysis of the role of SALL1 SUMOylation in the interaction 
with CBX4 
SUMOylation of SALL1 in not required for CBX4 interaction 
SALL1 post-translational modifications could affect its interaction with other 
proteins, for instance those that contain SIM domains as in the case of CBX4. As 
mentioned in the introduction, for a deeper analysis of SALL1 SUMOylation, our 
laboratory generated a SALL1ΔSUMO mutant in which four lysines were replaced by 
arginines (K571R, K592R, K982R and K1086R) loosing therefore the ability to be 
SUMOylated in cells and in vitro.  
In order to test whether SUMOylation could have a role on SALL1 binding to 





SALL1-2xHA and CMV-SALL1ΔSUMO-2xHA were transiently transfected in HEK 293FT 
cells together with CMV-CBX4-YFP (lanes 1 and 2 respectively) or with the empty vector 
CMV-YFP (lanes 3 and 4). A GFP-Trap pulldown was performed and analyzed by Western 
blot. Our results show that the SUMOylation-deficient mutant for SALL1 was still able to 
interact with CBX4. No visible differences were appreciated between WT SALL1 and 
SALL1ΔSUMO in the interaction with CBX4.  
 
Figure 41. Both SALL1 WT and SALL1ΔSUMO interact with CBX4. CMV-SALL1-2xHA and CMV-
SALL1ΔSUMO-2xHA were transfected in HEK 293FT cells together with CMV-CBX4-YFP or CMV-YFP alone. 
Proteins were pulled down using GFP beads and then analyzed by Western blot. As shown in the lanes 1 
and 2 of the Elution panel, both WT and mutant versions of SALL1 interact with CBX4. Molecular weight 
markers are shown to the right. Antibodies were used as indicated to the left. 
 
 
SALL1 SIM domains are not required for CBX4 interaction 
The results of the pulldowns previously shown demonstrated that the SALL1-
CBX4 interactions does not depend on the SUMOylation of SALL1 and that truncated 
mutant SALL1-826 maintains this interaction, suggesting that at least some interaction 
domain(s) could be located at the N-terminal part of the protein. By analyzing the full-







Figure 42. Identification of SIMs and SUMOylation sites in human SALL1 protein. Ovals 
represent the zinc fingers distributed along the protein. Q represents the poly-glutamine domain. In red, 
SUMO consensus sites mutated in SALL1ΔSUMO and, in blue, the predicted SIMs of SALL1.  
 
 
As shown in Figure 42, three out of the four predicted SIMs of SALL1, are located 
in the N-terminal part of the protein. Therefore, since CBX4 is known to be SUMOylated 
in vitro, we hypothesized a role of SALL1 SIMs in the interaction with CBX4. To 
investigate this possibility, we generated a SALL1ΔSIM version in which the four 
predicted SIMs were mutated. At first, the isoleucine (I) residues of the C-terminal SIM 
of SALL1 were mutated to lysine in order to destroy the hydrophobic core of the domain 
(ISVIQN > KSVKQN). Afterward, the hydrophobic and acidic residues of the three N-
terminal SIMs were mutated to alanine (VLIVN > AAAAN; VIIEN > AAAAN; ILLLA > 
AAAAA). Subsequently, to analyze whether the binding between SALL1 and CBX4 
requires SALL1 SIMs, we performed a pulldown experiment comparing the capability of 
SALL1 WT and both SUMO-related mutants to interact with CBX4 (Figure 43A). CMV-
SALL1-YFP, CMV-SALL1ΔSUMO-YFP or SALL1ΔSIM-YFP were transiently overexpressed in 
HEK 293FT cells together with CB6-CBX4-HA or CB6-HA alone. β-Actin was used as 
loading control. Despite our predictions, as shown in the lanes 4, 5 and 6 of the Elution 
panel, SALL1 WT, SALL1ΔSUMO and SALL1ΔSIM showed similar capacity to bind CBX4. 
Nevertheless, slight differences in the intensity of CBX4 signals between SALL1 WT, 





the initial levels of the YFP-fused proteins. Of note, SALL1ΔSUMO levels were higher 
compared to SALL1 WT, which is reflected in higher levels of CBX4-HA in the pulldown. 
Our experiments suggested that nor SALL1 SUMOylation or predicted SALL1 SIM sites 
were necessary for the interaction with CBX4.  
As shown in Figure 43A, the levels of CBX4 were higher when cells were 
transfected with SALL1 proteins. In order to test this, the levels of CBX4 in SALL1 WT, 
SALL1ΔSUMO, SALL1ΔSIM and YFP alone expressing cells were quantified in three 
independent experiment, normalized to the β-Actin levels, and plotted in a graph (Figure 
43B). In presence of SALL1 or any of its mutant forms, the levels of CBX4 were 
significantly higher than in YFP-transfected control cells. No significant differences in 






Figure 43. SUMO-related SALL1 mutants interact with CBX4 at the protein level. A) Western 
blot analysis of HEK 293FT cells transfected with CB6-CBX4-HA together with CMV-SALL1-YFP, CMV-
SALL1ΔSUMO-YFP, CMV-SALL1ΔSIM-YFP or CMV-YFP as control. Pulldowns were performed using the 
GFP-Trap technique. Interaction between CBX4 and WT SALL1 or SALL1 mutants was detected in the 
Elution. Molecular weight markers are shown to the right. Antibodies were used as indicated to the left. 
B) CBX4 levels in SALL1 WT, SALL1ΔSUMO, SALL1ΔSIM or YFP alone expressing cells were quantified, 
normalized to -Actin and reported as relative fold change. P-values were calculated on n= 3 using Mann 
Whitney test. *p< 0,05. Graph represents mean plus SEM. 
 
 
SUMO-related mutant forms of SALL1 do not localize to Pc bodies 
The mammalian cell nucleus contains several substructures, well defined despite 
the absence of a delineating membrane. Many types of nuclear “bodies” have been 
identified in the nucleus such as PML bodies and Pc bodies. Pc bodies are nuclear foci 
that show high concentration of PcG proteins and have been defined as centers of 
chromatin regulation for transcriptional repression of target genes. CBX4 localizes to the 
Pc bodies. SALL1 has been also reported to localize at nuclear bodies in cultured cells 
and in vivo, but the nature and function of these bodies are still unknown. In contrast to 
the results of SALL1-CBX4 interaction, previous experiments showed that SALL1 does 
not localize to Pc bodies. However, Proximity Ligation Assay (PLA) results obtained in the 
laboratory, showed the co-localization of SALL1 and CBX4 in the nucleoplasm (Pirone 
2016). Since the interaction between WT and mutant forms of SALL1 and CBX4 was 
demonstrated, we wondered whether mutations in SALL1 could influence the 
subcellular localization of the protein and, consequently, alter its localization respect to 
CBX4.  
SALL1 or its SUMO-related mutants fused to YFP were transfected into U2OS 
cells, where endogenous CBX4 was visualized by immunofluorescence using a specific 
anti-CBX4 antibody. Surprisingly, as shown in Figure 44, our confocal pictures showed 
that, despite the interaction between the two proteins, there was not co-localization of 
SALL1 and CBX4 in the nuclear bodies, neither the WT nor the SALL1ΔSUMO or 
SALL1ΔSIM mutant forms. Overall, these results indicated that SALL1 co-localizes with 






Figure 44. SALL1 WT or SUMO-related mutants do not co-localize with CBX4 at the nuclear 
bodies. Immunofluorescence confocal pictures of SALL1-YPF, SALL1ΔSUMO-YFP or SALL1ΔSIM-YFP 
expressed in U2OS cells (green), and endogenous CBX4 (magenta) using a specific antibody. Nuclei were 
stained with DAPI. Black and white pictures show single green or magenta channels. Arrowheads indicate 
SALL1 (green arrowheads) or Pc bodies (magenta arrowheads). 
 
 
Analysis of the SUMO binding capacity of SALL1 predicted SIMs 
The results obtained with the SALL1ΔSIM mutant form indicated that the 
identified SIMs were not involved in the binding to CBX4. We decided then to examine 
their capacity to bind SUMO in a no-covalent way. Hence, we generated constructs to 
produce three recombinant SUMO proteins in E. coli, fused to a GST-tag (Glutathione S-
transferase): GST-SUMO1-ΔGG, GST-SUMO2-ΔGG and GST-PolySUMO2. The C-terminal 
di-glycine motif of SUMO was removed to prevent covalent modifications. GST alone 
was used as a control. Protocol details are reported in Material and Methods section. 
Purified proteins were verified by Western blot as shown in Figure 45. The nitrocellulose 







Figure 45. Western blot analysis of recombinant GST-SUMO proteins. GST-SUMO1-ΔGG, GST-
SUMO2-ΔGG, GST-PolySUMO2 and GST-alone proteins were purified and analyzed by Western blot. 
Nitrocellulose membrane was stained with ponceau (right) and then proteins were recognized using an 
anti-GST antibody. Molecular weight markers are shown to the right. 
 
 
GST-fused proteins or GST alone were incubated with glutathione-beads. Next, 
charged beads were used for pulldown experiments. CMV-SALL1-YFP and CMV-
SALL1ΔSIM-YFP, as well as CMV-SALL1-826-YFP and CMV-SALL1-826 ΔSIM-YFP were 
transiently overexpressed in HEK 293FT cells and cell extracts were pulled down using 
the GST-SUMO beads. CMV-GFP-RNF4 was used as positive control since this protein is 
known to contain four tandem SIM repeats that preferentially interact with poly-SUMO 
chains versus SUMO moieties (Tatham et al. 2008). Conversely, CMV-
GFPGalactosidase (β-Gal) was used as negative control. Results were analyzed by 
Western blot (Figure 46). 
We could not detect the interaction of SALL1 WT, neither of SALL1-826 WT with 
the SUMO moieties, nor the polySUMO2 chains, in the Elution (panels 1 and 4, 
respectively), while the positive control RNF4 was detected in both SUMO2 and Poly-
SUMO 2 pulldowns (panel 3 of the Elution). However, no differences could be 





These experiments revealed that the predicted and selected SALL1 SIMs might not be 
functional, or alternatively, better tools should be use for their validation (see 
Discussion). In view of these results, the SIM mutant form of SALL1 was not taken into 
consideration for the following experiments. 
 
 
Figure 46. Analysis of SALL1 SIMS through GST-SUMO beads pulldown. Western blot analysis of 
SALL1-YFP or SALL1ΔSIM-YFP and SALL1-826 or SALL1-826 ΔSIM overexpressed in HEK 293FT cells and 
pulled down with GST-SUMO beads. GFP-RNF4 was used as positive control while GFP-β-Galactosidase 
was used as negative control. Molecular weight markers are shown to the right. Antibodies were used as 







4.3.3 Analysis of the functional effects of SALL1 – CBX4 interaction 
SALL1 increases endogenous CBX4 protein levels 
Previous results showed that, when co-transfected with SALL1, CBX4 protein 
levels were increased (Figure 43). In order to confirm those results, we transiently 
transfected HEK 293FT cells with CB6-CBX4-HA together with CMV-SALL1-YFP or with 
CMV-YFP alone. Western blot analysis revealed higher levels of CBX4-HA in presence of 
SALL1-YFP than in presence of YFP alone (Figure 47A).  
In order to discard any artefactual effect due to the overexpression conditions, 
we generated a HEK 293FT cell line expressing constitutively the GFS tagged (GFP-Flag-
Strep tag; see Materials and Methods section) version of SALL1. This cell line allowed us 
to obtain constant SALL1 expression levels moderately increased over the WT HEK 293FT 
cells. We analyzed the endogenous levels of CBX4 in HEK 293FT WT cells compared with 
GFS-SALL1 expressing cells. Western blot analysis showed increased levels of CBX4 in 
HEK 293FT_GFS-SALL1 cells compared with HEK 293FT WT cells (Figure 47B). 
 
Figure 47. SALL1 increases CBX4 protein levels. A) SALL1-YFP was transfected in HEK 293FT cells 
and CBX4-HA levels were detected by Western blot using anti-HA antibodies. B) Endogenous CBX4 levels 
in stable HEK 293FT GFS-SALL1 cells were higher than in HEK 293FT WT cells. Molecular weight markers 
are shown to the right. Antibodies were used as indicated to the left. 
 
 
In the interest to modulate the expression of SALL1 in cells, and so provide a 





293FT cell line using the inducible lentiviral TripZ vector (see Materials and Methods 
section). The HEK 293FT_TripZ-SALL1-2xHA cell line was based on the Tet-On system. 
Hence, this model allowed us to induce SALL1-2xHA expression in cells in a doxycycline 
dependent way, while the endogenous SALL1 expression was preserved.  
To test the effectiveness of this new cell model, we tested SALL1 expression at 
increasing concentrations of doxycycline. HEK 293FT_TripZ-SALL1-2xHA cells were 
treated with 1 ng, 10 ng, 0.1 µg or 1 µg per ml of doxycycline and the progressive 
increment of the SALL1 expression was verified by immunofluorescence (Figure 48A). 
SALL1-2xHA and endogenous SALL1 were detected using anti-SALL1 primary antibody 
and anti-mouse Alexa 488 secondary antibody. Confocal microscopy pictures showed 
how SALL1 signal, in green, increased according to doxycycline dose. The same doses of 
doxycycline were used to perform a Western blot experiment in which CBX4 protein 
levels were also analyzed (Figure 48B). The quantification of three independent 
experiments showed that CBX4 levels were significantly increased when the cells were 
treated with 1 µg of doxycycline compared to untreated cells (Figure 48C).  
 
SALL1 increases CBX4 levels at post-transcriptional level 
The experiments described above showed that CBX4 levels increased in presence 
of SALL1. As SALL1 is a transcription factor, we wondered whether this effect could due 
to the transcriptional activation of CBX4 expression in presence of SALL1, probably in an 
indirect way being SALL1 a transcriptional repressor. To address this possibility, we took 
advantage from the inducible HEK 293FT_TripZ-SALL1-2xHA cell model.  
Cells were treated with the above-mentioned concentration of doxycycline and 
SALL1 and CBX4 mRNA expression was analyzed by quantitative reverse transcription 
PCR (qPCR). As shown in Figure 48D, and consistent with previous results showing an 
increase in SALL1 protein levels, SALL1 mRNA expression increased in a doxycycline 
dependent manner. However, CBX4 mRNA expression levels did not vary significantly. 
Altogether these results demonstrated that high levels of SALL1 induce an increment of 







Figure 48. Analysis of SALL1 and CBX4 levels in HEK 293FT cell model. A) Immunofluorescence 
confocal  microscopy pictures of HEK 293FT_TripZ-SALL1-2xHA cells. Cells were treated with different 
concentration of doxycycline (dox) to induce SALL1 expression. SALL1-2xHA was detected using anti-SALL1 
primary antibody (green). Cell nuclei were stained with DAPI (blue). B) Western blot analysis showing 
CBX4 endogenous levels in 293FT_TripZ-SALL1-2xHA cells at different concentration of doxycycline. 
Molecular weight markers are shown to the right. Antibodies were used as indicated to the left. C) 
Quantification of 3 independent experiments. CBX4 values were normalized to -Actin. P-values were 
calculated using Two-way ANOVA test. * P-value < 0,05. D) qPCR of SALL1 and CBX4 mRNA expression at 
different concentrations of doxycycline in HEK 293FT_TripZ-SALL1-2xHA cells. SALL1 and CBX4 expression 






SALL1 influences size and number of Pc bodies 
One of the most important functions of CBX4 is its role as a member of the PRC1 
complex required for chromatin remodelling. As previously metioned in the 
introduction, PcG protein can form nuclear bodies as a result of the concentration of 
several chromatin repression points. The previous experiment demonstrated that SALL1 
does not co-localize with CBX4 in the Pc bodies, neither in its WT nor SUMOylation or 
SIM mutant forms. However, in light of the latest results, we decided to further analyze 
the relationship between these two proteins at the level of the Pc bodies via 
immunofluorescence.  
We transiently transfected CMV-SALL1-YFP or its mutant CMV-SALL1ΔSUMO-YFP 
in U2OS cells. CMV-GFP--Galactosidase (β-Gal) was transfected as control. While SALL1 
or SALL1ΔSUMO localized to nuclear bodies, β-Gal localized both in the nucleus and in 
the cytoplasm. To visualized CBX4 bodies, transfected cells were stained with specific 
CBX4 primary antibody (magenta).  
By analyzing confocal microscopy pictures, we observed that cells transfected 
with SALL1 or SALL1ΔSUMO showed a higher number of Pc bodies compared with the 
cells transfected with β-Gal (Figure 49A). Number of bodies, as well as the bodies area 
were examined in more than 100 cells per condition using Fiji software (Figure 49B-C). 
Our results showed that Pc bodies are significantly larger and more abundant in cells 
expressing SALL1 or SALL1ΔSUMO than in cells expressing β-Gal. However, no significant 
differences were observed between cells expressing SALL1 and SALL1ΔSUMO, neither in 
the number nor in the area of the Pc bodies. These results revealed that Pc bodies are 






Figure 49. Analysis of Pc bodies. A) Confocal microscopy images of U2OS cells expressing SALL1-
YFP, SALL1∆SUMO-YFP or β-Gal-GFP, visible in green. CBX4 bodies, in magenta, were stained with CBX4 
specific antibody. DAPI was used to stain cell nuclei. B) CBX4 bodies were counted and quantified as well 
as the CBX4 bodies areas using Fiji software and processed data were represented. Graph shows number 
of bodies per cell in the three different conditions. C) Graph shows the mean area of the bodies per cell 
per condition. P-values were calculated using One-way ANOVA test. ns: no significant; **** p< 0.0001. 
Error bars indicate mean plus SEM. Graphs represent mean with SEM. 
 
 
CBX4 targets are downregulated in presence of SALL1 
PcG multiprotein PRC1 complex plays a central role in the transcriptional 
silencing of target genes. Enhanced Pc bodies formation may lead to increased 
transcriptional repression of several target genes, including Hox genes, of which PcG 
proteins are well known regulators (Gonzalez et al. 2014; Cheutin and Cavalli 2018; 





number of CBX4 bodies, increased as consequence of SALL1 overexpression. Therefore, 
we hypothesized that this could produce an increased transcriptional repression of the 
CBX4 target genes. 
Among direct CBX4 targets, we selected genes belonging to Hox clusters and 
GATA family for their expression analysis. HEK 293FT cells were transiently transfected 
with CMV-SALL1-YFP, CMV-SALL1ΔSUMO-YFP or CMV-GFP-Galactosidase as control, 
and Hoxa11, Hoxb4, Hoxb7, Hoxb13, Hoxc6, Hoxc10, Hoxc12, Hoxd13 and GATA4 
expression levels were analyzed by qPCR. Our analysis showed significant differences in 
the expression levels of Hoxb4, Hoxb13, Hoxc6, Hoxc10 and GATA4 between SALL1 and 
β-GAL expressing cells (Figure 50). However, no significant differences were observed 
between SALL1ΔSUMO and control cells.  
Taken together, these results indicated that high SALL1 levels increases the 
transcriptional repression capacity of CBX4 on some of its target genes, probably by 
increasing CBX4 presence on chromatin. Interestingly, SUMOylation of SALL1 seemed to 






Figure 50. SALL1 expression downregulates CBX4 targets. Graphical representation of qPCR 
analysis of CBX4 target genes expression. HEK 293FT cells were transfected with CMV-SALL1-YFP (blue 
columns), CMV-SALL1∆SUMO-YFP (green columns) or CMV-GFPGAL as control (orange line). 
Afterwards, the expression levels of the indicated CBX4 target genes were analyzed by qPCR. Relative 
gene expression data were normalized on GAPDH and relative fold change over β-Gal expressing cells was 
represented. P-values were calculated on n= 5 using One-way ANOVA test. ns: no significant; *p< 0,05; 
**p<0,01. Graph represents mean plus SEM. 
 
SALL1 stabilizes CBX4 avoiding its degradation via the UPS  
Increasing the levels of a given protein can be linked to multiple cellular 
processes such as alteration in protein stability, changes in subcellular localization or 
protein degradation. The results obtained from the analysis of Pc bodies revealed that 
SALL1 is involved in the regulation of Pc bodies number and size. Moreover, SALL1 
overexpression increased the transcriptional repression capacity of CBX4 over its target 
genes. These findings led us to hypothesize that SALL1 could influence the formation of 
Pc bodies by stabilizing CBX4 and thus increasing its presence on the chromatin.  
In order to test this hypothesis, we analyzed the half-life of CBX4 by using 
cycloheximide (CHX). CHX treatment blocks the translational elongation of protein 
synthesis allowing the observation of the half-life of a protein of interest without 
confounding contributions from de novo translation. Therefore, in order to investigate 
whether SALL1 stabilizes CBX4 at the protein level, HEK 293FT cells were transfected 
with CMV-SALL1-YFP, CMV-SALL1ΔSUMO-YFP or CMV-GFP--Galactosidase and treated 
with 50 µg/ml of CHX in presence or absence of 10 µM of the proteasome inhibitor 
MG132. Cells were collected at different time points (0, 4, 8 and 16 hours after initiation 
of treatment) and CBX4 levels were analyzed by Western blot. Vinculin was used as 
loading control.  
This time-course experiment revealed that after 4 h of CHX treatment, the levels 
of CBX4 start to decrease. However, in SALL1 WT or SALL1ΔSUMO transfected cells the 
reduction in CBX4 levels was slower than in control cells (Figure 51A). Quantification of 
four independent experiments is shown in Figure 51B. When cells were co-treated with 
CHX and MG132 (Figure 51C), proteasome degradation was inhibited and CBX4 levels 





clear differences in the CBX4 levels were observed between cells transfected with SALL1, 
SALL1ΔSUMO or control (Figure 51D). Overall, these results suggested that in presence 
of SALL1 or SALL1ΔSUMO the levels of CBX4 decreased slower than in the control. 
Moreover, the accumulation of CBX4 levels in the cells treated with the MG132 
indicated that the CBX4 protein degradation occurs through the proteasome.  
Therefore, we concluded that SALL1 stabilizes CBX4 protein slowing down its 
degradation via the proteasome and that the SUMOylation of SALL1 seemed not 
essential for CBX4 stabilization.  
 
Figure 51. SALL1 stabilizes CBX4 protein. Cycloheximide chase experiments were performed in 
HEK 293FT cells transfected with CMV-SALL1-YFP, CMV-SALL1ΔSUMO-YFP or CMV-GFP--Galactosidase. 
Cells were treated with 50 µg/ml of cycloheximide (CHX) in presence (C) or absence (A) of 10 µM of the 
proteasome inhibitor MG132. Cells were collected at different time points (0, 4, 8 and 16 hours after 
initiation of treatment) and endogenous CBX4 levels were analyzed by Western blot. Vinculin was used as 
loading control. Molecular weight markers are shown to the right. Antibodies were used as indicated to 
the left. CBX4 levels were quantified after CHX treatment alone or in combination with MG132, 
normalized to Vinculin, and data from three different independent experiments were pooled together in 
the graphs B and D, respectively. The graph in B shows a trend of SALL1 WT or SALL1ΔSUMO in stabilizing 
CBX4 levels, although no significant differences were obtained by Two-way ANOVA test. Graphs represent 






CBX4 is degraded by the Ubiquitin-Proteasome System 
The degradation of proteins represents an important aspect of cell regulation. 
For example, proteins degradation is an essential process for the rapidly turnover of 
regulatory molecules, such as enzymes or transcription factors. In addition, as 
mentioned before, misfolded or damaged proteins are quickly degraded to prevent 
proteostasis alterations. In general, most of the proteins destined for degradation in the 
proteasome are previously marked with K48-linked polyubiquitin chains on specific 
lysine residues.  
Evidences reported in the literature have shown that CBX4 is covalently modified 
by ubiquitin before to be sent for degradation through the proteasome (Ning et al. 
2017). The bioUb system is an efficient strategy for the isolation of ubiquitin conjugates 
in cells (Pirone et al. 2017). This method is based on multicistronic expression from a 
single vector containing the E. coli biotin protein ligase BirA and an Avi-tag-fused to Ub. 
Avi-tag is a unique 15-amino acid peptide, which is specifically biotinylated by the BirA 
enzyme. Avi-tagged proteins can be purified using streptavidin beads. Denaturing 
conditions and stringent washes are used to inactivate deconjugating enzymes and 
remove Ub interactors, as well as non-specific background.  
We used this approach to investigate CBX4 modification in relation to SALL1 
expression. Therefore, we first tested the efficiency of this system to detect CBX4 
ubiquitinated fraction. We transiently transfected HEK 293FT cells with CB6-CBX4-HA 
together with CMV-BirA-2A-bioUb or CMV-BirA as control. Cells were treated with biotin 
in presence or absence of the protease inhibitor MG132. Protein lysates were processed 
for bioUb assay and results were analyzed by Western blot (Figure 52). Ubiquitinated 
CBX4 is shown in the Elution panel. A prominent band of 135 KDa and a 
polyubiquitination smear is shown, consistent with a poly-ubiquitinated form of CBX4. 
As expected, levels of ubiquitinated CBX4 increased in presence of the proteasome 
inhibitor. Anti-Avi-tag antibodies also showed an increase in the general ubiquitination 
levels in presence of MG132, as shown in the Elution panel. These results confirmed the 
modification of CBX4 by Ub and its degradation via UPS. In addition, they proved the 







Figure 52. CBX4 is ubiquitinated and degraded by the proteasome. Western blot of HEK 293FT 
cells transfected with CB6-CBX4-HA together with CMV-BirA-2A-bioUb or CMV-BirA as control. Cells were 
treated with 50 µM of biotin in presence or absence of 10 µM MG132. Protein lysates were incubated 
with streptavidin beads and were analyzed by Western blot. Molecular weight markers are shown to the 
right. Antibodies were used as indicated to the left. 
 
 
CBX4 ubiquitination is reduced in presence of SALL1 
In light of the obtained results, we speculated that SALL1 could increase CBX4 
stability, and consequently enhance its repressive function, by impairing its 
ubiquitination and subsequent proteasomal degradation. Initially, we planned to 
compare the ubiquitination levels of CBX4 after overexpression of SALL1, SALL1ΔSUMO 
or β-Gal. However, when more than three plasmids were transfected at the same time, 
we encountered difficulties to finely control the expression levels of the different 
overexpressed proteins. Thus, we decided to study CBX4 ubiquitination in the inducible 
TripZ-SALL1-2xHA cells. For this reason, we could not analyze the effect of SALL1ΔSUMO 
on CBX4 ubiquitination.  
TripZ-SALL1-2xHA cells were transiently transfected with CMV-CBX4-YFP 





with 1 µg/ml of doxycycline, in presence or absence of 10 µM of MG132. Protein lysates 
were passed through streptavidin beads to isolate bio-ubiquitin conjugated proteins and 
results were analyzed by Western blot (Figure 53A). According to our hypothesis, a 
statistically significant reduction of CBX4 ubiquitination was observed in presence of 
high levels of SALL1 (Figure 53B, upper panel). However, in presence of MG132, no 
significant differences were appreciated between induced and not induced cells (Figure 
53B, lower panel). These results indicated that SALL1 is able to stabilize CBX4 protein by 
reducing its ubiquitination and subsequent degradation via the proteasome.  
 
Figure 53. Analysis of the effect of SALL1 on CBX4 ubiquitination by bioUb assay. A) Western 
blot of HEK TripZ-SALL1-2xHA cells transiently transfected with CMV-CBX4-YFP together with CMV-BirA-
2A-bioUb or CMV-BirA as control. The cells were treated or not with 1 µg/ml of dox, in presence or absence 
of 10 µM of MG132. Protein lysates were passed through streptavidin beads to isolate bioUb conjugated 
proteins and results were analyzed by Western blot. β-Actin was used as loading control. B) The levels of 
ubiquitinated CBX4 in doxycycline induced and not induced cells, in presence (bottom panel) or absence 
(upper panel) of MG132, were quantified and normalized to the CBX4 levels in the input. P-values were 








4.4 Discussion  
Townes-Brocks syndrome is a rare disease caused by mutations in the zinc-finger 
transcriptional repressor SALL1 and characterized by a spectrum of malformations in 
digits, ears and kidneys. Mutations in SALL1 gene are associated with the presence of a 
truncated form of the protein that, in contrast to the WT that resides primarily in the 
nucleus (Sato et al. 2004), localizes to the cytoplasm and impedes primary cilia function 
(Bozal-Basterra et al. 2018).  
Understanding the function and regulation of proteins is essential to understand 
how cells work and to advance in the treatment of diseases. The study of post-
translational modifications can reveal much about proteins regulation. PTMs, in fact, can 
influence numerous properties of proteins including protein interactions, localization, 
and half-life. In Drosophila, SUMOylation of Sall proteins alter their nuclear localization, 
as well as their transcriptional repressor activity (Sánchez et al. 2010; 2011). Previous 
results obtained in our laboratory had confirmed SALL1 SUMOylation in human cells. 
Furthermore, a proximity proteomics approach combined with MS analysis was used to 
identify possible interactors of human SALL1 (Bozal-Basterra et al. 2018). Among them, 
GO analysis revealed that the SUMO ligase term was well represented in the list of 
interacting factors. Since the genetic interaction between sall genes and Pc had been 
previously described to be important during Drosophila embryogenesis, the E3 SUMO 
ligase CBX4 was chosen for further investigation and, at first, was hypothesized as 
possible E3 SUMO ligase involved in SALL1 SUMOylation. Many efforts have been made 
in the past to address this possibility. In vitro results were compatible with a role of CBX4 
promoting the SUMOylation of SALL1 (unpublished results). However, the results 
obtained in cells were inconclusive mostly due to technical difficulties experienced 
during the performance of the experiments (Pirone 2016). Whether the interaction 
between CBX4 and SALL1 could have an important role in cellular function and 
regulation beyond SUMOylation, and the mechanisms underlying this interaction, had 







In this work, we confirmed that SALL1 and CBX4 interact with each other at the 
protein level. Moreover, using the truncated SALL1-826 mutant we demonstrated that 
the domain(s) of interaction between SALL1 and CBX4 could be located at the N-terminal 
part of the protein.  
The N-terminal part of SALL1 contains important features that determine TBS 
etiology. This region contains a conserved PolyQ domain involved in dimerization with 
other SALL family members (Sweetman et al. 2003), a zinc finger (ZF1) conserved in 
mammals and a conserved 12 amino acids sequence through which it interacts with the 
NuRD complex to mediate transcriptional repression (Kiefer et al. 2002; Lauberth and 
Rauchman 2006). Is any of these motifs involved in CBX4 binding? In order to define the 
precise site of SALL1 binding to CBX4, different SALL1 truncated mutants could be 
generated to analyze the minimal residues needed for the interaction. This strategy 
would also help to study whether the ZF1, a C2HC-type zinc finger that might mediate 
protein-protein interactions rather than DNA binding (Laity, Lee, and Wright 2001), 
could have a role in the interaction with CBX4, as well as with other proteins. 
By analyzing the full-length amino acid sequence, three SIMs of SALL1 were 
predicted and, interestingly, two of them were located at the N-terminal part of SALL1. 
The results obtained with the SALL1ΔSIM mutant form or the truncated version SALL1-
826ΔSIM indicated that the identified SIMs were not necessary for the binding of SALL1 
to CBX4. However, it should be noted that these experiments were performed on cells 
that maintained the endogenous version of SALL1. Therefore, it cannot be excluded that 
binding to CBX4 was still carried out by the WT moiety through the dimerization of 
endogenous and overexpressed SALL1 forms. In vitro experiments or the use of a SALL1-
KO cell line might help to clarify the role of those moieties in the interaction with CBX4. 
On the other hand, it should be considered that we were not able to prove the binding 
capacity of these SIM sequences to SUMO. A deeper investigation of those predicted 
SIMs by different tools, as well as the selection and test of other predicted SALL1 SIMs 
would be necessary to clarify the properties of these SALL1 domains.  
CBX4 also contains two functional SIMs, both of which contribute to its SUMO E3 





et al. 2010). Therefore, we also hypothesized that CBX4 SIMs would be involved in its 
binding with SALL1 when SUMOylated. However, our results demonstrated that 
SALL1ΔSUMO mutant was still able to interact with CBX4 suggesting that SUMOylation 
of SALL1 is not required for CBX4 interaction. Nevertheless, the possible contribution of 
the endogenous SALL1 in the interaction should be considered.  
 
Involvement of SALL1 SUMOylation in Pc bodies regulation and CBX4 stability 
In cells, CBX4 localizes to the Pc bodies, which have been defined as centers of 
chromatin regulation for transcriptional repression of target genes (Entrevan, 
Schuettengruber, and Cavalli 2016). Previous experiments showed the co-localization of 
SALL1 and CBX4 in the nucleoplasm by PLA (Pirone 2016). However, in spite of their 
interaction, neither SALL1 WT nor the SALL1ΔSUMO or SALL1ΔSIM mutant forms 
showed co-localization with CBX4 in the nuclear bodies, indicating that the SALL1-CBX4 
interaction do not occurs on chromatin.  
Although it does not co-localize to Pc bodies, we demonstrated that SALL1, as 
well as its SUMOylation-deficient mutant form, affect the Pc bodies formation, which 
appear more abundant and bigger. The non-localization of SALL1 at Pc bodies could be 
explained considering its binding with CBX4 as a dynamic and transitory interaction. 
SALL1 could interact with CBX4 in the nucleoplasm altering its levels but it would not be 
involved in the formation of PC bodies. Indeed, in this work we demonstrated that SALL1 
stabilizes and increases CBX4 protein levels in a post-translational way, reducing its 
ubiquitination with subsequent reduction of its degradation via the proteasome. 
Interestingly, a not significant effect was previously observed on Pc bodies in presence 
of the truncated SALL1-826 form (Pirone 2016). 
Different scenarios could explain our results. As a transcriptional repressor, 
SALL1 could be inhibiting the transcription of ubiquitin E3 ligase(s) involved in CBX4 
modification, such is the CHIP (STUB1) ubiquitin E3 ligase, and so impairing its 
degradation (Wang et al. 2020). Alternatively, SALL1 binding could reduce CBX4 
ubiquitination by decreasing its recognition by the ubiquitin E3 ligase. For instance, at 
least in the case of CHIP, CBX4 phosphorylation is required for its ubiquitin-mediated 





impeding CBX4 ubiquitination by CHIP. Also, SALL1 could be facilitating the binding 
and/or the recognition of CBX4 by DUBs such as USP26, a known deubiquitinase for 
CBX4 (Ning et al. 2017). Further experiments are required to investigate these 
possibilities. The identification of the E3 ligase involved in CBX4 ubiquitination in this 
context will open the way to ulterior experiments. Moreover, DUBs inhibitors could be 
used to test whether these enzymes could have a role in this regulatory process.  
Furthermore, in this work we also demonstrated that high SALL1 levels increase 
the transcriptional repression capacity of CBX4 on some of its target genes. Although it 
seems not necessary for CBX4 protein levels regulation, the results obtained by qPCR 
analysis indicated that SUMOylation of SALL1 is important to modulate the 
transcriptional repression activity of CBX4 on some gene targets. Therefore, the binding 
to SALL1 might be sufficient for CBX4 stabilization; however, only when SALL1 is 
SUMOylated, the recruitment of CBX4 on the chromatin results in a functional effect. 
One possible explanation of these results could be the involvement of a third 
component. For instance, SUMOylation of SALL1 could facilitate the contemporary 
interaction with other members of the PRC1, such as RING1 or PHC1. Interestingly, those 
factors were also found as possible SALL1 interactors in the MS analysis of the BioID 
(Bozal-Basterra et al. 2018). Otherwise, SUMOylation of SALL1 could facilitate the 
interaction with co-factor required for chromatin silencing. For example, the 
corepressor KAP1 binds PRC1 enhancing its binding at the promoters of differentiation-
inducible genes and  their transcriptional repression (Cheng, Ren, and Kerppola 2014). 
This interpretation could be translated into the following model. SALL1 would 
interact with CBX4, either in its SUMOylated form or as an unmodified protein. This 
interaction would result in less ubiquitination of CBX4 with its consequent stabilization. 
Thus, CBX4 would be recruited on chromatin, either via PREs or by the recognition of 
the H3K27me3 mark, where it would act as a transcriptional repressor of its target genes 
directly or promoting the chromatin remodeling via PRC1. However, the mere presence 
of CBX4 on chromatin would not be sufficient for its function (Figure 54A). When SALL1 
is SUMOylated, in addition to interacting with CBX4, it would also be able to interact 
with repression cofactors or other components of PRC1, which will be recruited on 





components of PRC1, would result in the activation of the multiprotein complex with 
consequent repression of the target genes (Figure 54B-1).  
Alternatively, SUMOylated SALL1 could enhance CBX4 repression capacity by 
facilitating its SUMOylation. The SUMOylation of CBX4 is known to be necessary for its 
repression activity on the chromatin (Kang et al. 2010). Previous results obtained in our 
laboratory by bioSUMO assay, showed that in presence of high levels of SALL1, the 
SUMOylation of CBX4 increased (Pirone 2016). However, this result was not easy to 
interpret due to the increased total levels of the protein. In addition, SALL1 was 
demonstrated to interact with UBC9 and SUMO1 in a yeast two-hybrid system (Netzer 
et al. 2002). Interestingly, some members of the SUMOylation pathway were also found 
in in the MS analysis of the BioID (Bozal-Basterra et al. 2018). In this alternative scenario, 
once it promoted CBX4 stabilization impairing its ubiquitination, SUMOylated SALL1 
would be able also to promote CBX4 SUMOylation by recruiting an E3 SUMO ligase or 
other components of the SUMOylation machinery (Figure 54B-2). Unlike in the previous 
hypothesized model in which it would be SALL1-independent, in this case CBX4 
SUMOylation would be dependent of SALL1.  
Interestingly, a prediction analysis of CBX4 ubiquitination sites by UbPred 
(http://www.ubpred.org/), revealed that the K224 involved in CBX4 SUMOylation, could 
also works as ubiquitination site. Additionally, the adjacent K209 and K247 were 
predicted as high score ubiquitination sites. In light of this, we could also speculate that 
PTM of CBX4 by ubiquitin and SUMO would be mutually exclusive events and that SALL1 
might be involved in their regulation. Further experiments are necessary to corroborate 
the feasibility of both these hypothesized scenarios, which, actually, are not mutually 
exclusive.  
The validation of the interaction of SALL1 WT and SALL1ΔSUMO with PRC1 
proteins and SUMOylation machinery components by pulldown assay would give us a 
starting point for the design of the following key experiments. Moreover, a chromatin 
immunoprecipitation assay could be performed to verify the presence of CBX4 on the 






Figure 54. Schematic model of possible regulatory scenarios between SALL1 and CBX4. A) SALL1 
binds and stabilizes CBX4 impeding its ubiquitination and its consequent degradation by the proteasome. 
CBX4 stabilization entails an increment of its protein levels and its accumulation at the Pc bodies but not 
an increase of its transcriptional repression capacity. However, when SUMOylated SALL1 binds CBX4 this 
interaction translates into transcriptional repression of its target genes. B-1) This effect could be due to 
the contemporary recruitment of other essential transcription factors. B-2) Alternatively, although non-
exclusively, SUMOylated SALL1 could increase CBX4 transcriptional repression facilitating its SUMOylation 
via the recruitment of SUMOylation machinery components.  
 
 
Altogether, these results suggest that SALL1 plays an important role in the 
control of the expression of key developmental genes through post-transcriptional 
regulation of CBX4. The loss of SALL1 SUMOylation, originated by the truncation of 
SALL1, could alter the regulation of important genes during development, which could 
eventually contribute to the TBS onset. The elucidation of the SALL1-CBX4 interaction 
could help to better understand the role of SALL1 during normal development and clarify 










































The concept of proteostasis, and specially its maintenance, is essential to 
understand the cause of diseases associated with alterations in proteins misfolding, 
degradation, trafficking or aggregation. Proteostasis preservation is ensured by a set of 
interacting pathways that are critical for the proper functioning of the cell. Alteration of 
those regulatory processes can seriously affect cellular functions and cause the onset of 
diseases, including rare diseases such as TBS and CEP.  
Rare diseases affect a small number of people compared to the general 
population (less than 1 in 2000 people) and are usually characterized by specific and 
uncommon issues. Because of their unusual nature, rare diseases often risk being 
neglected by the pharmacological industry and research policies. However, even though 
a single rare disease can affect only one person in a million, overall rare disease patients 
comprise about 7% of the EU population. Besides, these patients often have serious 
clinical manifestations and fewer available options for treatment.  
Investigating the underlying mechanism of rare diseases can lead to interesting 
scientific discoveries. The research into rare diseases may help us to understand 
fundamental mechanisms of human biology and disease, often applicable to disorders 
that are more prevalent. For example, research on Liddle syndrome (a rare inherited 
kidney disorder associated with early and severe hypertension) has contributed to 
increase the knowledge about the pathology of hypertension, and studies of Fanconi 
anemia have illuminated disease mechanisms of bone marrow failure, cancer, and 
resistance to chemotherapy (Lifton, Gharavi, and Geller 2001; D’Andrea 2010). 
Examining how and why a gene is not working properly in a particular disease can also 
help to discover more about its function under normal conditions, which in turn can 
shine light on the function of other genes that interact with it, as well as help to our 
understanding of related common diseases. Vice versa, the analysis of the physiological 
regulation of a disease-causing gene may help us to understand or unveil the 
pathological consequences of its alteration.  
This thesis work was focused on two different rare diseases: Townes-Brock 
Syndrome and Congenital Erythropoietic Porphyria. Both diseases are extremely rare 





each of these conditions are different, as well as the premises that drove our research 
interest on them. 
Although numerous advances have been made in understanding the molecular 
alterations of the disease, CEP remains a metabolic disorder for which no effective 
treatments are available yet. In addition, the lack of adequate models makes the study 
of new possible therapies even more difficult. A new humanized and inducible CEP C73R 
mouse could improve drug discovery by providing a more useful model that could 
partially solve viability and health problems experienced with previous models, 
facilitating experimental procedures. 
TBS presents developmental defects that are known to be caused by mutations 
in SALL1. Recently, TBS has been proposed to be a ciliopathy, as the truncated SALL1 
might interfere with primary cilia regulation (Bozal-Basterra et al. 2018). However, very 
little is known about the function of this transcription factor, which makes difficult to 
understand the molecular basis of the disease. The discovery of a role for SALL1 in the 
regulation of chromatin remodelling and modulation of developmental gene expression 
through the regulation of CBX4 could shed light on its role in human development and 
help to better understand molecular mechanism underlying TBS.  
In summary, the results obtained throughout this work constitute a step forward 
in the understanding of SALL1 function, and would help to advance in the development 
of new CEP therapies, as well as to improve our knowledge about the pathogenesis of 




























The results obtained along this thesis on the analysis of the UROS-C73R humanized and 
inducible mouse cell model for CEP lead to the following conclusions: 
I. Upon FLEX-Switch construct insertion by CRISPR/Cas9, human UROS correctly 
replaces and rescues mouse UROS function. 
 
II. Upon tamoxifen induction of Cre recombinase, UROS WT allele is correctly 
converted to express the mutant C73R version.  
 
III. FACS and HPLC analyses confirmed increased porphyrin levels after induction by 
tamoxifen.  
 
IV. MG132 and ciclopirox treatments cause a reduction in porphyrin levels. 
 
V. This cellular model represent a valid CEP model. 
 
The results obtained along this thesis on the analysis of the relation between SALL1 and 
CBX4 lead to the following conclusions: 
I. SALL1 interacts with CBX4 at the protein level, probably through its N-terminal 
part domain(s).  
 
II. SALL1-826 truncated mutant interact with CBX4 at protein level.  
 
III. SUMOylation of SALL1 is not required for its interaction with CBX4. 
 
IV. The analyzed SALL1 SIMs domains are not required for its interaction with CBX4. 
 
V. SALL1, as well as its SUMO-related mutants, do not co-localize with CBX4 at Pc 






VI. At high levels of SALL1, as well as of its SUMO-related mutants, endogenous CBX4 
protein levels increase.  
 
VII. SALL1 increases CBX4 levels at post-transcriptional level. 
 
VIII. SALL1, as well as its SALL1ΔSUMO mutant form, influences size and number of 
Pc bodies, which appeared more abundant and larger.  
 
IX. CBX4 targets are downregulated in presence of high levels of SALL1, however not 
in presence of its SALL1ΔSUMO mutant form. 
 
X. SALL1 stabilizes CBX4 impairing its ubiquitination and consequent degradation 


















































Aizencang, G., C. Solis, D. F. Bishop, C. Warner, y R. J. Desnick. 2000. «Human 
Uroporphyrinogen-III Synthase: Genomic Organization, Alternative Promoters, 
and Erythroid-Specific Expression». Genomics 70 (2): 223-31. 
https://doi.org/10.1006/geno.2000.6373. 
Aranda, Sergi, Gloria Mas, y Luciano Di Croce. 2015. «Regulation of Gene Transcription 
by Polycomb Proteins». Science Advances 1 (11): e1500737. 
https://doi.org/10.1126/sciadv.1500737. 
Arnold, Konstantin, Lorenza Bordoli, Jürgen Kopp, y Torsten Schwede. 2006. «The 
SWISS-MODEL Workspace: A Web-Based Environment for Protein Structure 
Homology Modelling». Bioinformatics (Oxford, England) 22 (2): 195-201. 
https://doi.org/10.1093/bioinformatics/bti770. 
Aronson, Boaz E., Kelly A. Stapleton, y Stephen D. Krasinski. 2014. «Role of GATA Factors 
in Development, Differentiation, and Homeostasis of the Small Intestinal 
Epithelium». American Journal of Physiology. Gastrointestinal and Liver 
Physiology 306 (6): G474-490. https://doi.org/10.1152/ajpgi.00119.2013. 
Balch, William E., Richard I. Morimoto, Andrew Dillin, y Jeffery W. Kelly. 2008. «Adapting 
Proteostasis for Disease Intervention». Science (New York, N.Y.) 319 (5865): 916-
19. https://doi.org/10.1126/science.1141448. 
Balwani, Manisha, y Robert J. Desnick. 2012. «The Porphyrias: Advances in Diagnosis and 
Treatment». Blood 120 (23): 4496-4504. https://doi.org/10.1182/blood-2012-
05-423186. 
Benkert, Pascal, Marco Biasini, y Torsten Schwede. 2011. «Toward the Estimation of the 
Absolute Quality of Individual Protein Structure Models». Bioinformatics 
(Oxford, England) 27 (3): 343-50. 
https://doi.org/10.1093/bioinformatics/btq662. 
Bett, John S. 2016. «Proteostasis Regulation by the Ubiquitin System». Essays in 
Biochemistry 60 (2): 143-51. https://doi.org/10.1042/EBC20160001. 
Bhagavan N. V., Chung-Eun Ha. 2015. Essentials of Medical Biochemistry With Clinical 
Cases. Second edition. Vol. Chapter 27. Elsevier. 
Biasini, Marco, Stefan Bienert, Andrew Waterhouse, Konstantin Arnold, Gabriel Studer, 
Tobias Schmidt, Florian Kiefer, et al. 2014. «SWISS-MODEL: Modelling Protein 
Tertiary and Quaternary Structure Using Evolutionary Information». Nucleic 
Acids Research 42 (Web Server issue): W252-258. 
https://doi.org/10.1093/nar/gku340. 
Bishop, David F., Sonia Clavero, Narla Mohandas, y Robert J. Desnick. 2011. «Congenital 
Erythropoietic Porphyria: Characterization of Murine Models of the Severe 
Common (C73R/C73R) and Later-Onset Genotypes». Molecular Medicine 
(Cambridge, Mass.) 17 (7-8): 748-56. 
https://doi.org/10.2119/molmed.2010.00258. 
Bishop, David F., Annika Johansson, Robert Phelps, Amr A. Shady, Maria C. M. Ramirez, 
Makiko Yasuda, Andres Caro, y Robert J. Desnick. 2006. «Uroporphyrinogen III 
Synthase Knock-in Mice Have the Human Congenital Erythropoietic Porphyria 
Phenotype, Including the Characteristic Light-Induced Cutaneous Lesions». 
American Journal of Human Genetics 78 (4): 645-58. 
https://doi.org/10.1086/502667. 
Blouin, Jean-Marc, Yann Duchartre, Pierre Costet, Magalie Lalanne, Cécile Ged, Ana Lain, 





Potential of Proteasome Inhibitors in Congenital Erythropoietic Porphyria». 
Proceedings of the National Academy of Sciences of the United States of America 
110 (45): 18238-43. https://doi.org/10.1073/pnas.1314177110. 
Bohren, Kurt M., Varsha Nadkarni, Jian H. Song, Kenneth H. Gabbay, y David Owerbach. 
2004. «A M55V Polymorphism in a Novel SUMO Gene (SUMO-4) Differentially 
Activates Heat Shock Transcription Factors and Is Associated with Susceptibility 
to Type I Diabetes Mellitus». The Journal of Biological Chemistry 279 (26): 27233-
38. https://doi.org/10.1074/jbc.M402273200. 
Borozdin, Wiktor, Katharina Steinmann, Beate Albrecht, Armand Bottani, Koenraad 
Devriendt, Michael Leipoldt, y Jürgen Kohlhase. 2006. «Detection of 
Heterozygous SALL1 Deletions by Quantitative Real Time PCR Proves the 
Contribution of a SALL1 Dosage Effect in the Pathogenesis of Townes-Brocks 
Syndrome». Human Mutation 27 (2): 211-12. 
https://doi.org/10.1002/humu.9396. 
Botzenhart, Elke M., Gabriella Bartalini, Edward Blair, Angela F. Brady, Frances Elmslie, 
Karen L. Chong, Katie Christy, et al. 2007. «Townes-Brocks Syndrome: Twenty 
Novel SALL1 Mutations in Sporadic and Familial Cases and Refinement of the 
SALL1 Hot Spot Region». Human Mutation 28 (2): 204-5. 
https://doi.org/10.1002/humu.9476. 
Botzenhart, Elke M., Andrew Green, Helena Ilyina, Rainer König, R. Brian Lowry, Ivan F. 
M. Lo, Mordechai Shohat, et al. 2005. «SALL1 Mutation Analysis in Townes-
Brocks Syndrome: Twelve Novel Mutations and Expansion of the Phenotype». 
Human Mutation 26 (3): 282. https://doi.org/10.1002/humu.9362. 
Boyer, Laurie A., Kathrin Plath, Julia Zeitlinger, Tobias Brambrink, Lea A. Medeiros, Tong 
Ihn Lee, Stuart S. Levine, et al. 2006. «Polycomb Complexes Repress 
Developmental Regulators in Murine Embryonic Stem Cells». Nature 441 (7091): 
349-53. https://doi.org/10.1038/nature04733. 
Bozal-Basterra, Laura, Itziar Martín-Ruíz, Lucia Pirone, Yinwen Liang, Jón Otti Sigurðsson, 
Maria Gonzalez-Santamarta, Immacolata Giordano, et al. 2018. «Truncated 
SALL1 Impedes Primary Cilia Function in Townes-Brocks Syndrome». American 
Journal of Human Genetics 102 (2): 249-65. 
https://doi.org/10.1016/j.ajhg.2017.12.017. 
Bracken, Adrian P., y Kristian Helin. 2009. «Polycomb Group Proteins: Navigators of 
Lineage Pathways Led Astray in Cancer». Nature Reviews. Cancer 9 (11): 773-84. 
https://doi.org/10.1038/nrc2736. 
Brehme, Marc, y Cindy Voisine. 2016. «Model Systems of Protein-Misfolding Diseases 
Reveal Chaperone Modifiers of Proteotoxicity». Disease Models & Mechanisms 
9 (8): 823-38. https://doi.org/10.1242/dmm.024703. 
Brehme, Marc, Cindy Voisine, Thomas Rolland, Shinichiro Wachi, James H. Soper, Yitan 
Zhu, Kai Orton, et al. 2014. «A Chaperome Subnetwork Safeguards Proteostasis 
in Aging and Neurodegenerative Disease». Cell Reports 9 (3): 1135-50. 
https://doi.org/10.1016/j.celrep.2014.09.042. 
Cantera, Rafael, Karin Lüer, Tor Erik Rusten, Rosa Barrio, Fotis C. Kafatos, y Gerhard M. 
Technau. 2002. «Mutations in Spalt Cause a Severe but Reversible 
Neurodegenerative Phenotype in the Embryonic Central Nervous System of 






Cañadas, Victoria, Isidre Vilacosta, Isidoro Bruna, y Valentin Fuster. 2010. «Marfan 
Syndrome. Part 1: Pathophysiology and Diagnosis». Nature Reviews. Cardiology 
7 (5): 256-65. https://doi.org/10.1038/nrcardio.2010.30. 
Cappadocia, Laurent, y Christopher D. Lima. 2018. «Ubiquitin-like Protein Conjugation: 
Structures, Chemistry, and Mechanism». Chemical Reviews 118 (3): 889-918. 
https://doi.org/10.1021/acs.chemrev.6b00737. 
Casanova, Jordi. 1989. «Mutations in Thespalt Gene OfDrosophila Cause Ectopic 
Expression OfUltrabithorax AndSex Combs Reduced». Roux’s Archives of 
Developmental Biology: The Official Organ of the EDBO 198 (3): 137-40. 
https://doi.org/10.1007/BF02438938. 
Celen, Arda B., y Umut Sahin. 2020. «Sumoylation on Its 25th Anniversary: Mechanisms, 
Pathology, and Emerging Concepts». The FEBS Journal, abril. 
https://doi.org/10.1111/febs.15319. 
Celis, J. F. de, y R. Barrio. 2000. «Function of the Spalt/Spalt-Related Gene Complex in 
Positioning the Veins in the Drosophila Wing». Mechanisms of Development 91 
(1-2): 31-41. https://doi.org/10.1016/s0925-4773(99)00261-0. 
Celis, Jose F. de, y Rosa Barrio. 2009. «Regulation and Function of Spalt Proteins during 
Animal Development». The International Journal of Developmental Biology 53 
(8-10): 1385-98. https://doi.org/10.1387/ijdb.072408jd. 
Chen, Qingbo, Lei Huang, Dongning Pan, Lihua J. Zhu, y Yong-Xu Wang. 2018. «Cbx4 
Sumoylates Prdm16 to Regulate Adipose Tissue Thermogenesis». Cell Reports 22 
(11): 2860-72. https://doi.org/10.1016/j.celrep.2018.02.057. 
Cheng, Bo, Xiaojun Ren, and Tom K. Kerppola. 2014. «KAP1 Represses Differentiation-
Inducible Genes in Embryonic Stem Cells through Cooperative Binding with PRC1 
and Derepresses Pluripotency-Associated Genes». Molecular and Cellular 
Biology 34 (11): 2075-91. https://doi.org/10.1128/MCB.01729-13. 
Cheutin, Thierry, and Giacomo Cavalli. 2018. «Loss of PRC1 Induces Higher-Order 
Opening of Hox Loci Independently of Transcription during Drosophila 
Embryogenesis». Nature Communications 9 (1): 3898. 
https://doi.org/10.1038/s41467-018-05945-4. 
Chiabrando, Deborah, Sonia Mercurio, and Emanuela Tolosano. 2014. «Heme and 
Erythropoieis: More than a Structural Role». Haematologica 99 (6): 973-83. 
https://doi.org/10.3324/haematol.2013.091991. 
Cimino, Patrick J., and David H. Gutmann. 2018. «Neurofibromatosis Type 1». Handbook 
of Clinical Neurology 148: 799-811. https://doi.org/10.1016/B978-0-444-64076-
5.00051-X. 
Cundiff, Mary D., Christina M. Hurley, Jeremy D. Wong, Joseph A. Boscia, Aarti Bashyal, 
Jake Rosenberg, Eden L. Reichard, Nicholas D. Nassif, Jennifer S. Brodbelt, and 
Daniel A. Kraut. 2019. «Ubiquitin Receptors Are Required for Substrate-
Mediated Activation of the Proteasome’s Unfolding Ability». Scientific Reports 9 
(1): 14506. https://doi.org/10.1038/s41598-019-50857-and. 
D’Andrea, Alan D. 2010. «Susceptibility Pathways in Fanconi’s Anemia and Breast 
Cancer». The New England Journal of Medicine 362 (20): 1909-19. 
https://doi.org/10.1056/NEJMra0809889. 
David, Gregory, Mychell A. Neptune, and Ronald A. DePinho. 2002. «SUMO-1 





Activities». The Journal of Biological Chemistry 277 (26): 23658-63. 
https://doi.org/10.1074/jbc.M203690200. 
Deschamps, Jacqueline, and Denis Duboule. 2017. «Embryonic Timing, Axial Stem Cells, 
Chromatin Dynamics, and the Hox Clock». Genes & Development 31 (14): 1406-
16. https://doi.org/10.1101/gad.303123.117. 
Desnick, R. J., I. A. Glass, W. Xu, C. Solis, and K. H. Astrin. 1998. «Molecular Genetics of 
Congenital Erythropoietic Porphyria». Seminars in Liver Disease 18 (1): 77-84. 
https://doi.org/10.1055/s-2007-1007143. 
Di Pierro, Elena, Valentina Brancaleoni, and Francesca Granata. 2016. «Advances in 
Understanding the Pathogenesis of Congenital Erythropoietic Porphyria». British 
Journal of Haematology 173 (3): 365-79. https://doi.org/10.1111/bjh.13978. 
Dissmeyer, Nico, Olivier Coux, Manuel S. Rodriguez, Rosa Barrio, and Core Group 
Members of PROTEOSTASIS. 2019. «PROTEOSTASIS: A European Network to 
Break Barriers and Integrate Science on Protein Homeostasis». Trends in 
Biochemical Sciences 44 (5): 383-87. https://doi.org/10.1016/j.tibs.2019.01.007. 
Dupuis-Girod, Sophie, Véronique Akkari, Cécile Ged, Claire Galambrun, Kamila Kebaïli, 
Jean-Charles Deybach, Alain Claudy, et al. 2005. «Successful Match-Unrelated 
Donor Bone Marrow Transplantation for Congenital Erythropoietic Porphyria 
(Günther Disease)». European Journal of Pediatrics 164 (2): 104-7. 
https://doi.org/10.1007/s00431-004-1575-x. 
Eifler, Karolin, and Alfred C. O. Vertegaal. 2015. «Mapping the SUMOylated Landscape». 
The FEBS Journal 282 (19): 3669-80. https://doi.org/10.1111/febs.13378. 
Enserink, Jorrit M. 2015. «Sumo and the Cellular Stress Response». Cell Division 10: 4. 
https://doi.org/10.1186/s13008-015-0010-1. 
Entrevan, Marianne, Bernd Schuettengruber, and Giacomo Cavalli. 2016. «Regulation of 
Genome Architecture and Function by Polycomb Proteins». Trends in Cell Biology 
26 (7): 511-25. https://doi.org/10.1016/j.tcb.2016.04.009. 
Erwin, Angelika, Manisha Balwani, Robert J. Desnick, and Porphyrias Consortium of the 
NIH-Sponsored Rare Diseases Clinical Research Network. 1993. «Congenital 
Erythropoietic Porphyria». En GeneReviews®, editado por Margaret P. Adam, 
Holly H. Ardinger, Roberta A. Pagon, Stephanie E. Wallace, Lora JH Bean, Karen 
Stephens, and Anne Amemiya. Seattle (WA): University of Washington, Seattle. 
http://www.ncbi.nlm.nih.gov/books/NBK154652/. 
Eskeland, R., E. Freyer, M. Leeb, A. Wutz, and W. A. Bickmore. 2010. «Histone 
Acetylation and the Maintenance of Chromatin Compaction by Polycomb 
Repressive Complexes». Cold Spring Harbor Symposia on Quantitative Biology 
75: 71-78. https://doi.org/10.1101/sqb.2010.75.053. 
Farshi, Pershang, Rahul R. Deshmukh, Joseph O. Nwankwo, Richard T. Arkwright, Boris 
Cvek, Jinbao Liu, and Q. Ping Dou. 2015. «Deubiquitinases (DUBs) and DUB 
Inhibitors: A Patent Review». Expert Opinion on Therapeutic Patents 25 (10): 
1191-1208. https://doi.org/10.1517/13543776.2015.1056737. 
Fortian, Arola, David Castaño, Gabriel Ortega, Ana Laín, Miquel Pons, and Oscar Millet. 
2009. «Uroporphyrinogen III Synthase Mutations Related to Congenital 
Erythropoietic Porphyria Identify a Key Helix for Protein Stability». Biochemistry 
48 (2): 454-61. https://doi.org/10.1021/bi801731q. 
Fortian, Arola, Esperanza González, David Castaño, Juan M. Falcon-Perez, and Oscar 





in Enzymes Carrying the Hotspot Mutation C73R». The Journal of Biological 
Chemistry 286 (15): 13127-33. https://doi.org/10.1074/jbc.M110.205849. 
Frank, J., X. Wang, H. M. Lam, V. M. Aita, F. K. Jugert, G. Goerz, H. F. Merk, M. B. Poh-
Fitzpatrick, and A. M. Christiano. 1998. «C73R Is a Hotspot Mutation in the 
Uroporphyrinogen III Synthase Gene in Congenital Erythropoietic Porphyria». 
Annals of Human Genetics 62 (Pt 3): 225-30. https://doi.org/10.1046/j.1469-
1809.1998.6230225.x. 
Friedel, Roland H., Wolfgang Wurst, Benedikt Wefers, and Ralf Kühn. 2011. «Generating 
Conditional Knockout Mice». Methods in Molecular Biology (Clifton, N.J.) 693: 
205-31. https://doi.org/10.1007/978-1-60761-974-1_12. 
Fritsch, C., K. Bolsen, T. Ruzicka, and G. Goerz. 1997. «Congenital Erythropoietic 
Porphyria». Journal of the American Academy of Dermatology 36 (4): 594-610. 
https://doi.org/10.1016/s0190-9622(97)70249-4. 
Fu, Yanfang, Jeffry D. Sander, Deepak Reyon, Vincent M. Cascio, and J. Keith Joung. 2014. 
«Improving CRISPR-Cas Nuclease Specificity Using Truncated Guide RNAs». 
Nature Biotechnology 32 (3): 279-84. https://doi.org/10.1038/nbt.2808. 
Gao, Zhonghua, Jin Zhang, Roberto Bonasio, Francesco Strino, Ayana Sawai, Fabio Parisi, 
Yuval Kluger, and Danny Reinberg. 2012. «PCGF Homologs, CBX Proteins, and 
RYBP Define Functionally Distinct PRC1 Family Complexes». Molecular Cell 45 (3): 
344-56. https://doi.org/10.1016/j.molcel.2012.01.002. 
Garvin, Alexander J. 2019. «Beyond Reversal: Ubiquitin and Ubiquitin-like Proteases and 
the Orchestration of the DNA Double Strand Break Repair Response». 
Biochemical Society Transactions 47 (6): 1881-93. 
https://doi.org/10.1042/BST20190534. 
Ged, C., F. Moreau-Gaudry, E. Richard, E. Robert-Richard, and H. de Verneuil. 2009. 
«Congenital Erythropoietic Porphyria: Mutation Update and Correlations 
between Genotype and Phenotype». Cellular and Molecular Biology (Noisy-Le-
Grand, France) 55 (1): 53-60. 
Gonzalez, Inma, Julio Mateos-Langerak, Aubin Thomas, Thierry Cheutin, and Giacomo 
Cavalli. 2014. «Identification of Regulators of the Three-Dimensional Polycomb 
Organization by a Microscopy-Based Genome-Wide RNAi Screen». Molecular 
Cell 54 (3): 485-99. https://doi.org/10.1016/j.molcel.2014.03.004. 
Gu, Bin, Eszter Posfai, and Janet Rossant. 2018. «Efficient Generation of Targeted Large 
Insertions by Microinjection into Two-Cell-Stage Mouse Embryos». Nature 
Biotechnology 36 (7): 632-37. https://doi.org/10.1038/nbt.4166. 
Haneef, S. A. Syed, and C. George Priya Doss. 2016. «Personalized Pharmacoperones for 
Lysosomal Storage Disorder: Approach for Next-Generation Treatment». 
Advances in Protein Chemistry and Structural Biology 102: 225-65. 
https://doi.org/10.1016/bs.apcsb.2015.10.001. 
Hartl, F. Ulrich, Andreas Bracher, and Manajit Hayer-Hartl. 2011. «Molecular 
Chaperones in Protein Folding and Proteostasis». Nature 475 (7356): 324-32. 
https://doi.org/10.1038/nature10317. 
Hendriks, Ivo A., and Alfred C. O. Vertegaal. 2016a. «A Comprehensive Compilation of 






Hendriks, Ivo A., and Alfred C. O. Vertegaal. 2016b. «A High-Yield Double-Purification 
Proteomics Strategy for the Identification of SUMO Sites». Nature Protocols 11 
(9): 1630-49. https://doi.org/10.1038/nprot.2016.082. 
Hietakangas, Ville, Julius Anckar, Henri A. Blomster, Mitsuaki Fujimoto, Jorma J. Palvimo, 
Akira Nakai, and Lea Sistonen. 2006. «PDSM, a Motif for Phosphorylation-
Dependent SUMO Modification». Proceedings of the National Academy of 
Sciences of the United States of America 103 (1): 45-50. 
https://doi.org/10.1073/pnas.0503698102. 
Hipp, Mark S., Prasad Kasturi, and F. Ulrich Hartl. 2019. «The Proteostasis Network and 
Its Decline in Ageing». Nature Reviews. Molecular Cell Biology 20 (7): 421-35. 
https://doi.org/10.1038/s41580-019-0101-and. 
Hipp, Mark S., Sae-Hun Park, and F. Ulrich Hartl. 2014. «Proteostasis Impairment in 
Protein-Misfolding and -Aggregation Diseases». Trends in Cell Biology 24 (9): 
506-14. https://doi.org/10.1016/j.tcb.2014.05.003. 
Hochstrasser, Mark. 2009. «Origin and Function of Ubiquitin-like Proteins». Nature 458 
(7237): 422-29. https://doi.org/10.1038/nature07958. 
Hogeling, Marcia, Taizo Nakano, Christopher C. Dvorak, Sheilagh Maguiness, and Ilona J. 
Frieden. 2011. «Severe Neonatal Congenital Erythropoietic Porphyria». Pediatric 
Dermatology 28 (4): 416-20. https://doi.org/10.1111/j.1525-1470.2010.01376.x. 
Ismail, Ismail Hassan, Jean-Philippe Gagné, Marie-Christine Caron, Darin McDonald, 
Zhizhong Xu, Jean-Yves Masson, Guy G. Poirier, and Michael J. Hendzel. 2012. 
«CBX4-Mediated SUMO Modification Regulates BMI1 Recruitment at Sites of 
DNA Damage». Nucleic Acids Research 40 (12): 5497-5510. 
https://doi.org/10.1093/nar/gks222. 
Jayaraj, Gopal G., Mark S. Hipp, and F. Ulrich Hartl. 2020. «Functional Modules of the 
Proteostasis Network». Cold Spring Harbor Perspectives in Biology 12 (1). 
https://doi.org/10.1101/cshperspect.a033951. 
Jones, Takako, and Peter L. Jones. 2018. «A Cre-Inducible DUX4 Transgenic Mouse 
Model for Investigating Facioscapulohumeral Muscular Dystrophy». PloS One 13 
(2): e0192657. https://doi.org/10.1371/journal.pone.0192657. 
Justice, Monica J., and Paraminder Dhillon. 2016. «Using the Mouse to Model Human 
Disease: Increasing Validity and Reproducibility». Disease Models & Mechanisms 
9 (2): 101-3. https://doi.org/10.1242/dmm.024547. 
Kagey, Michael H., Tiffany A. Melhuish, and David Wotton. 2003. «The Polycomb Protein 
Pc2 Is a SUMO E3». Cell 113 (1): 127-37. https://doi.org/10.1016/s0092-
8674(03)00159-4. 
Kang, Xunlei, Yitao Qi, Yong Zuo, Qi Wang, Yanqiong Zou, Robert J. Schwartz, Jinke 
Cheng, and Edward T. H. Yeh. 2010. «SUMO-Specific Protease 2 Is Essential for 
Suppression of Polycomb Group Protein-Mediated Gene Silencing during 
Embryonic Development». Molecular Cell 38 (2): 191-201. 
https://doi.org/10.1016/j.molcel.2010.03.005. 
Katsumura, Koichi R., Emery H. Bresnick, and GATA Factor Mechanisms Group. 2017. 
«The GATA Factor Revolution in Hematology». Blood 129 (15): 2092-2102. 
https://doi.org/10.1182/blood-2016-09-687871. 
Katugampola, R. P., A. V. Anstey, A. AND. Finlay, S. Whatley, J. Woolf, N. Mason, J. C. 





Porphyria Derived from a Study of 29 Cases». The British Journal of Dermatology 
167 (4): 888-900. https://doi.org/10.1111/j.1365-2133.2012.11154.x. 
Katugampola, R. P., M. N. Badminton, A. AND. Finlay, S. Whatley, J. Woolf, N. Mason, J. 
C. Deybach, et al. 2012. «Congenital Erythropoietic Porphyria: A Single-Observer 
Clinical Study of 29 Cases». The British Journal of Dermatology 167 (4): 901-13. 
https://doi.org/10.1111/j.1365-2133.2012.11160.x. 
Kauffman, L., D. I. Evans, R. F. Stevens, and C. Weinkove. 1991. «Bone-Marrow 
Transplantation for Congenital Erythropoietic Porphyria». Lancet (London, 
England) 337 (8756): 1510-11. https://doi.org/10.1016/0140-6736(91)93198-i. 
Kelberman, Daniel, Lily Islam, Jörn Lakowski, Chiara Bacchelli, Estelle Chanudet, 
Francesco Lescai, Aara Patel, et al. 2014. «Mutation of SALL2 Causes Recessive 
Ocular Coloboma in Humans and Mice». Human Molecular Genetics 23 (10): 
2511-26. https://doi.org/10.1093/hmg/ddt643. 
Kiefer, Susan McLeskey, Bradley W. McDill, Jing Yang, and Michael Rauchman. 2002. 
«Murine Sall1 Represses Transcription by Recruiting a Histone Deacetylase 
Complex». The Journal of Biological Chemistry 277 (17): 14869-76. 
https://doi.org/10.1074/jbc.M200052200. 
Kiefer, Susan McLeskey, Kevin K. Ohlemiller, Jing Yang, Bradley W. McDill, Jürgen 
Kohlhase, and Michael Rauchman. 2003. «Expression of a Truncated Sall1 
Transcriptional Repressor Is Responsible for Townes-Brocks Syndrome Birth 
Defects». Human Molecular Genetics 12 (17): 2221-27. 
https://doi.org/10.1093/hmg/ddg233. 
Klauke, Karin, Višnja Radulović, Mathilde Broekhuis, Ellen Weersing, Erik Zwart, Sandra 
Olthof, Martha Ritsema, et al. 2013. «Polycomb Cbx Family Members Mediate 
the Balance between Haematopoietic Stem Cell Self-Renewal and 
Differentiation». Nature Cell Biology 15 (4): 353-62. 
https://doi.org/10.1038/ncb2701. 
Kohlhase, J., A. Wischermann, H. Reichenbach, U. Froster, and W. Engel. 1998. 
«Mutations in the SALL1 Putative Transcription Factor Gene Cause Townes-
Brocks Syndrome». Nature Genetics 18 (1): 81-83. 
https://doi.org/10.1038/ng0198-81. 
Kohlhase, Jürgen, Marielle Heinrich, Lucia Schubert, Manuela Liebers, Andreas Kispert, 
Franco Laccone, Peter Turnpenny, Robin M. Winter, and William Reardon. 2002. 
«Okihiro Syndrome Is Caused by SALL4 Mutations». Human Molecular Genetics 
11 (23): 2979-87. https://doi.org/10.1093/hmg/11.23.2979. 
Laity, J. H., B. M. Lee, and P. E. Wright. 2001. «Zinc Finger Proteins: New Insights into 
Structural and Functional Diversity». Current Opinion in Structural Biology 11 (1): 
39-46. https://doi.org/10.1016/s0959-440x(00)00167-6. 
Landecker, H. L., D. A. Sinclair, and H. W. Brock. 1994. «Screen for Enhancers of 
Polycomb and Polycomblike in Drosophila Melanogaster». Developmental 
Genetics 15 (5): 425-34. https://doi.org/10.1002/dvg.1020150505. 
Lauberth, Shannon M., Amy C. Bilyeu, Beth A. Firulli, Kristen L. Kroll, and Michael 
Rauchman. 2007. «A Phosphomimetic Mutation in the Sall1 Repression Motif 
Disrupts Recruitment of the Nucleosome Remodeling and Deacetylase Complex 






Lauberth, Shannon M., and Michael Rauchman. 2006. «A Conserved 12-Amino Acid 
Motif in Sall1 Recruits the Nucleosome Remodeling and Deacetylase Corepressor 
Complex». The Journal of Biological Chemistry 281 (33): 23922-31. 
https://doi.org/10.1074/jbc.M513461200. 
Lee, Bongyong, and Mark T. Muller. 2009. «SUMOylation Enhances DNA 
Methyltransferase 1 Activity». The Biochemical Journal 421 (3): 449-61. 
https://doi.org/10.1042/BJ20090142. 
Li, Bing, Jing Zhou, Peng Liu, Jialei Hu, Hong Jin, Yohei Shimono, Masahide Takahashi, 
and Guoliang Xu. 2007. «Polycomb Protein Cbx4 Promotes SUMO Modification 
of de Novo DNA Methyltransferase Dnmt3a». The Biochemical Journal 405 (2): 
369-78. https://doi.org/10.1042/BJ20061873. 
Li, Jie, Ying Xu, HuiKe Jiao, Wei Wang, Zhu Mei, and GuoQiang Chen. 2014. «Sumoylation 
of Hypoxia Inducible Factor-1α and Its Significance in Cancer». Science China. Life 
Sciences 57 (7): 657-64. https://doi.org/10.1007/s11427-014-4685-3. 
Lifton, R. P., A. G. Gharavi, and D. S. Geller. 2001. «Molecular Mechanisms of Human 
Hypertension». Cell 104 (4): 545-56. https://doi.org/10.1016/s0092-
8674(01)00241-0. 
Ma, Yuanwu, Lianfeng Zhang, and Xingxu Huang. 2014. «Genome Modification by 
CRISPR/Cas9». The FEBS Journal 281 (23): 5186-93. 
https://doi.org/10.1111/febs.13110. 
Mardaryev, Andrei N., Bo Liu, Valentina Rapisarda, Krzysztof Poterlowicz, Igor 
Malashchuk, Jana Rudolf, Andrey A. Sharov, et al. 2016. «Cbx4 Maintains the 
Epithelial Lineage Identity and Cell Proliferation in the Developing Stratified 
Epithelium». The Journal of Cell Biology 212 (1): 77-89. 
https://doi.org/10.1083/jcb.201506065. 
Matic, Ivan, Joost Schimmel, Ivo A. Hendriks, Maria A. van Santen, Frans van de Rijke, 
Hans van Dam, Florian Gnad, Matthias Mann, and Alfred C. O. Vertegaal. 2010. 
«Site-Specific Identification of SUMO-2 Targets in Cells Reveals an Inverted 
SUMOylation Motif and a Hydrophobic Cluster SUMOylation Motif». Molecular 
Cell 39 (4): 641-52. https://doi.org/10.1016/j.molcel.2010.07.026. 
Merino, Anna, Jordi To-Figueras, and Carmen Herrero. 2006. «Atypical Red Cell 
Inclusions in Congenital Erythropoietic Porphyria». British Journal of 
Haematology 132 (2): 124. https://doi.org/10.1111/j.1365-2141.2005.05726.x. 
Merrill, Jacqueline C., Tiffany A. Melhuish, Michael H. Kagey, Shen-Hsi Yang, Andrew D. 
Sharrocks, and David Wotton. 2010. «A Role for Non-Covalent SUMO Interaction 
Motifs in Pc2/CBX4 E3 Activity». PloS One 5 (1): e8794. 
https://doi.org/10.1371/journal.pone.0008794. 
Minden, Mark D., Donna E. Hogge, Scott J. Weir, Jim Kasper, Debra A. Webster, Lavonne 
Patton, Yulia Jitkova, et al. 2014. «Oral Ciclopirox Olamine Displays Biological 
Activity in a Phase I Study in Patients with Advanced Hematologic Malignancies». 
American Journal of Hematology 89 (4): 363-68. 
https://doi.org/10.1002/ajh.23640. 
Misawa, Kiyoshi, Yuki Misawa, Atsushi Imai, Daiki Mochizuki, Shiori Endo, Masato Mima, 
Ryuji Ishikawa, Hideya Kawasaki, Takashi Yamatodani, and Takeharu Kanazawa. 
2018. «Epigenetic Modification of SALL1 as a Novel Biomarker for the Prognosis 






Mohamed, Fedah E., Lihadh Al-Gazali, Fatma Al-Jasmi, and Bassam R. Ali. 2017. 
«Pharmaceutical Chaperones and Proteostasis Regulators in the Therapy of 
Lysosomal Storage Disorders: Current Perspective and Future Promises». 
Frontiers in Pharmacology 8: 448. https://doi.org/10.3389/fphar.2017.00448. 
Morey, Lluis, Luigi Aloia, Luca Cozzuto, Salvador Aznar Benitah, and Luciano Di Croce. 
2013. «RYBP and Cbx7 Define Specific Biological Functions of Polycomb 
Complexes in Mouse Embryonic Stem Cells». Cell Reports 3 (1): 60-69. 
https://doi.org/10.1016/j.celrep.2012.11.026. 
Nakajo, S., K. Omata, T. Aiuchi, T. Shibayama, I. Okahashi, H. Ochiai, AND. Nakai, K. 
Nakaya, and AND. Nakamura. 1990. «Purification and Characterization of a Novel 
Brain-Specific 14-KDa Protein». Journal of Neurochemistry 55 (6): 2031-38. 
https://doi.org/10.1111/j.1471-4159.1990.tb05792.x. 
Netzer, Christian, Stefan K. Bohlander, Markus Hinzke, Ying Chen, and Jürgen Kohlhase. 
2006. «Defining the Heterochromatin Localization and Repression Domains of 
SALL1». Biochimica Et Biophysica Acta 1762 (3): 386-91. 
https://doi.org/10.1016/j.bbadis.2005.12.005. 
Netzer, Christian, Stefan K. Bohlander, Leonie Rieger, Stefan Müller, and Jürgen 
Kohlhase. 2002. «Interaction of the Developmental Regulator SALL1 with UBE2I 
and SUMO-1». Biochemical and Biophysical Research Communications 296 (4): 
870-76. https://doi.org/10.1016/s0006-291x(02)02003-x. 
Ning, Bo, Wei Zhao, Chen Qian, Pinghua Liu, Qingtian Li, Wenyuan Li, and Rong-Fu Wang. 
2017. «USP26 Functions as a Negative Regulator of Cellular Reprogramming by 
Stabilising PRC1 Complex Components». Nature Communications 8 (1): 349. 
https://doi.org/10.1038/s41467-017-00301-4. 
Ohkuni, Kentaro, Nagesh Pasupala, Jennifer Peek, Grace Lauren Holloway, Gloria D. 
Sclar, Reuben Levy-Myers, Richard E. Baker, Munira A. Basrai, and Oliver 
Kerscher. 2018. «SUMO-Targeted Ubiquitin Ligases (STUbLs) Reduce the Toxicity 
and Abnormal Transcriptional Activity Associated With a Mutant, Aggregation-
Prone Fragment of Huntingtin». Frontiers in Genetics 9: 379. 
https://doi.org/10.3389/fgene.2018.00379. 
Osinalde, Nerea, Anna Duarri, Juanma Ramirez, Rosa Barrio, Guiomar Perez de 
Nanclares, and Ugo Mayor. 2019. «Impaired Proteostasis in Rare Neurological 
Diseases». Seminars in Cell & Developmental Biology 93: 164-77. 
https://doi.org/10.1016/j.semcdb.2018.10.007. 
Phillips, John D., David P. Steensma, Michael A. Pulsipher, Gerald J. Spangrude, and 
James P. Kushner. 2007. «Congenital Erythropoietic Porphyria Due to a Mutation 
in GATA1: The First Trans-Acting Mutation Causative for a Human Porphyria». 
Blood 109 (6): 2618-21. https://doi.org/10.1182/blood-2006-06-022848. 
Pineault, Kyriel M., Ana Novoa, Anastasiia Lozovska, Deneen M. Wellik, and Moises 
Mallo. 2019. «Two CRISPR/Cas9-Mediated Methods for Targeting Complex 
Insertions, Deletions, or Replacements in Mouse». MethodsX 6: 2088-2100. 
https://doi.org/10.1016/j.mex.2019.09.003. 
Pirone, Lucia. 2016. «Post-translational modification by SUMO and Ubiquitin-Like 
proteins; Role of SUMOylation on SALL proteins». Thesis Doctoral. 
Pirone, Lucia, Wendy Xolalpa, Jón Otti Sigurðsson, Juanma Ramirez, Coralia Pérez, 





Platform for the Analysis of Ubiquitin-like Protein Modifications Using in Vivo 
Biotinylation». Scientific Reports 7: 40756. https://doi.org/10.1038/srep40756. 
Pober, Barbara R. 2010. «Williams-Beuren Syndrome». The New England Journal of 
Medicine 362 (3): 239-52. https://doi.org/10.1056/NEJMra0903074. 
Powell, C. M., and R. C. Michaelis. 1999. «Townes-Brocks Syndrome». Journal of Medical 
Genetics 36 (2): 89-93. 
Powers, Evan T., Richard I. Morimoto, Andrew Dillin, Jeffery W. Kelly, and William E. 
Balch. 2009. «Biological and Chemical Approaches to Diseases of Proteostasis 
Deficiency». Annual Review of Biochemistry 78: 959-91. 
https://doi.org/10.1146/annurev.biochem.052308.114844. 
Ramanujam, Vaithamanithi-Mudumbai Sadagopa, and Karl Elmo Anderson. 2015. 
«Porphyria Diagnostics-Part 1: A Brief Overview of the Porphyrias». Current 
Protocols in Human Genetics 86 (julio): 17.20.1-17.20.26. 
https://doi.org/10.1002/0471142905.hg1720s86. 
Ren, Xiaoqing, Boqiang Hu, Moshi Song, Zhichao Ding, Yujiao Dang, Zunpeng Liu, Weiqi 
Zhang, et al. 2019. «Maintenance of Nucleolar Homeostasis by CBX4 Alleviates 
Senescence and Osteoarthritis». Cell Reports 26 (13): 3643-3656.e7. 
https://doi.org/10.1016/j.celrep.2019.02.088. 
Roux, Kyle J., Dae In Kim, Manfred Raida, and Brian Burke. 2012. «A Promiscuous Biotin 
Ligase Fusion Protein Identifies Proximal and Interacting Proteins in Mammalian 
Cells». The Journal of Cell Biology 196 (6): 801-10. 
https://doi.org/10.1083/jcb.201112098. 
Sánchez, Jonatan, Ana Talamillo, Monika González, Luis Sánchez-Pulido, Silvia Jiménez, 
Lucia Pirone, James D. Sutherland, and Rosa Barrio. 2011. «Drosophila Sal and 
Salr Are Transcriptional Repressors». The Biochemical Journal 438 (3): 437-45. 
https://doi.org/10.1042/BJ20110229. 
Sánchez, Jonatan, Ana Talamillo, Fernando Lopitz-Otsoa, Coralia Pérez, Roland Hjerpe, 
James D. Sutherland, Leire Herboso, Manuel S. Rodríguez, and Rosa Barrio. 2010. 
«Sumoylation Modulates the Activity of Spalt-like Proteins during Wing 
Development in Drosophila». The Journal of Biological Chemistry 285 (33): 
25841-49. https://doi.org/10.1074/jbc.M110.124024. 
Sato, Akira, Shosei Kishida, Toshiya Tanaka, Akira Kikuchi, Tatsuhiko Kodama, Makoto 
Asashima, and Ryuichi Nishinakamura. 2004. «Sall1, a Causative Gene for 
Townes-Brocks Syndrome, Enhances the Canonical Wnt Signaling by Localizing 
to Heterochromatin». Biochemical and Biophysical Research Communications 
319 (1): 103-13. https://doi.org/10.1016/j.bbrc.2004.04.156. 
Schnütgen, Frank, Nathalie Doerflinger, Cécile Calléja, Olivia Wendling, Pierre Chambon, 
and Norbert B. Ghyselinck. 2003. «A Directional Strategy for Monitoring Cre-
Mediated Recombination at the Cellular Level in the Mouse». Nature 
Biotechnology 21 (5): 562-65. https://doi.org/10.1038/nbt811. 
Seeler, Jacob-Sebastian, and Anne Dejean. 2017. «SUMO and the Robustness of 
Cancer». Nature Reviews. Cancer 17 (3): 184-97. 
https://doi.org/10.1038/nrc.2016.143. 
Shen, Tao, and Shile Huang. 2016. «Repositioning the Old Fungicide Ciclopirox for New 






Simon, Jeffrey A., and Robert E. Kingston. 2009. «Mechanisms of Polycomb Gene 
Silencing: Knowns and Unknowns». Nature Reviews. Molecular Cell Biology 10 
(10): 697-708. https://doi.org/10.1038/nrm2763. 
Soria-Bretones, Isabel, Cristina Cepeda-García, Cintia Checa-Rodriguez, Vincent Heyer, 
Bernardo Reina-San-Martin, Evi Soutoglou, and Pablo Huertas. 2017. «DNA End 
Resection Requires Constitutive Sumoylation of CtIP by CBX4». Nature 
Communications 8 (1): 113. https://doi.org/10.1038/s41467-017-00183-6. 
Soshnikova, Natalia. 2014. «Hox Genes Regulation in Vertebrates». Developmental 
Dynamics: An Official Publication of the American Association of Anatomists 243 
(1): 49-58. https://doi.org/10.1002/dvdy.24014. 
Swatek, Kirby N., and David Komander. 2016. «Ubiquitin Modifications». Cell Research 
26 (4): 399-422. https://doi.org/10.1038/cr.2016.39. 
Sweetman, Dylan, Terry Smith, Elizabeth R. Farrell, Andrew Chantry, and Andrea 
Munsterberg. 2003. «The Conserved Glutamine-Rich Region of Chick Csal1 and 
Csal3 Mediates Protein Interactions with Other Spalt Family Members. 
Implications for Townes-Brocks Syndrome». The Journal of Biological Chemistry 
278 (8): 6560-66. https://doi.org/10.1074/jbc.M209066200. 
Szymczak-Workman, Andrea L., Kate M. Vignali, and Dario A. A. Vignali. 2012. «Design 
and Construction of 2A Peptide-Linked Multicistronic Vectors». Cold Spring 
Harbor Protocols 2012 (2): 199-204. https://doi.org/10.1101/pdb.ip067876. 
Taipale, J., J. K. Chen, M. K. Cooper, B. Wang, R. K. Mann, L. Milenkovic, M. P. Scott, and 
P. A. Beachy. 2000. «Effects of Oncogenic Mutations in Smoothened and Patched 
Can Be Reversed by Cyclopamine». Nature 406 (6799): 1005-9. 
https://doi.org/10.1038/35023008. 
Talamillo, Ana, Orhi Barroso-Gomila, Immacolata Giordano, Leiore Ajuria, Marco Grillo, 
Ugo Mayor, and Rosa Barrio. 2020. «The Role of SUMOylation during 
Development». Biochemical Society Transactions 48 (2): 463-78. 
https://doi.org/10.1042/BST20190390. 
Tatham, Michael H., Marie-Claude Geoffroy, Linnan Shen, Anna Plechanovova, Neil 
Hattersley, Ellis G. Jaffray, Jorma J. Palvimo, and Ronald T. Hay. 2008. «RNF4 Is a 
Poly-SUMO-Specific E3 Ubiquitin Ligase Required for Arsenic-Induced PML 
Degradation». Nature Cell Biology 10 (5): 538-46. 
https://doi.org/10.1038/ncb1716. 
Thomas, Tynisha, Kieran Seay, Jian Hua Zheng, Cong Zhang, Christina Ochsenbauer, John 
C. Kappes, and Harris Goldstein. 2016. «High-Throughput Humanized Mouse 
Models for Evaluation of HIV-1 Therapeutics and Pathogenesis». Methods in 
Molecular Biology (Clifton, N.J.) 1354: 221-35. https://doi.org/10.1007/978-1-
4939-3046-3_15. 
Urquiza, Pedro, Ana Laín, Arantza Sanz-Parra, Jorge Moreno, Ganeko Bernardo-
Seisdedos, Pierre Dubus, Esperanza González, et al. 2018. «Repurposing 
Ciclopirox as a Pharmacological Chaperone in a Model of Congenital 
Erythropoietic Porphyria». Science Translational Medicine 10 (459). 
https://doi.org/10.1126/scitranslmed.aat7467. 
Uygun, David S., Zhiwen Ye, Anna AND. Zecharia, Edward C. Harding, Xiao Yu, Raquel 
Yustos, Alexei L. Vyssotski, Stephen G. Brickley, Nicholas P. Franks, and William 
Wisden. 2016. «Bottom-Up versus Top-Down Induction of Sleep by Zolpidem 





The Official Journal of the Society for Neuroscience 36 (44): 11171-84. 
https://doi.org/10.1523/JNEUROSCI.3714-15.2016. 
Walsh, Nicole C., Laurie L. Kenney, Sonal Jangalwe, Ken-Edwin Aryee, Dale L. Greiner, 
Michael A. Brehm, and Leonard D. Shultz. 2017. «Humanized Mouse Models of 
Clinical Disease». Annual Review of Pathology 12 (enero): 187-215. 
https://doi.org/10.1146/annurev-pathol-052016-100332. 
Wang, Xin, Liping Li, Yuanzhong Wu, Ruhua Zhang, Meifang Zhang, Dan Liao, Gang Wang, 
Ge Qin, Rui-Hua Xu, and Tiebang Kang. 2016. «CBX4 Suppresses Metastasis via 
Recruitment of HDAC3 to the Runx2 Promoter in Colorectal Carcinoma». Cancer 
Research 76 (24): 7277-89. https://doi.org/10.1158/0008-5472.CAN-16-2100. 
Wang, Xin, Ge Qin, Xiaoting Liang, Wen Wang, Zhuo Wang, Dan Liao, Li Zhong, et al. 
2020. «Targeting the CK1α/CBX4 Axis for Metastasis in Osteosarcoma». Nature 
Communications 11 (1): 1141. https://doi.org/10.1038/s41467-020-14870-4. 
Webb, Bryn D., Sanjeeva Metikala, Patricia G. Wheeler, Mingma D. Sherpa, Sander M. 
Houten, Marko E. Horb, and Eric E. Schadt. 2017. «Heterozygous Pathogenic 
Variant in DACT1 Causes an Autosomal-Dominant Syndrome with Features 
Overlapping Townes-Brocks Syndrome». Human Mutation 38 (4): 373-77. 
https://doi.org/10.1002/humu.23171. 
Wei, Fang, Hans R. Schöler, and Michael L. Atchison. 2007. «Sumoylation of Oct4 
Enhances Its Stability, DNA Binding, and Transactivation». The Journal of 
Biological Chemistry 282 (29): 21551-60. 
https://doi.org/10.1074/jbc.M611041200. 
Weir, S. J., L. Patton, K. Castle, L. Rajewski, J. Kasper, and A. D. Schimmer. 2011. «The 
Repositioning of the Anti-Fungal Agent Ciclopirox Olamine as a Novel 
Therapeutic Agent for the Treatment of Haematologic Malignancy». Journal of 
Clinical Pharmacy and Therapeutics 36 (2): 128-34. 
https://doi.org/10.1111/j.1365-2710.2010.01172.x. 
Wotton, D., and J. C. Merrill. 2007. «Pc2 and SUMOylation». Biochemical Society 
Transactions 35 (Pt 6): 1401-4. https://doi.org/10.1042/BST0351401. 
Yang, Hui, Haoyi Wang, Chikdu S. Shivalila, Albert W. Cheng, Linyu Shi, and Rudolf 
Jaenisch. 2013. «One-Step Generation of Mice Carrying Reporter and Conditional 
Alleles by CRISPR/Cas-Mediated Genome Engineering». Cell 154 (6): 1370-79. 
https://doi.org/10.1016/j.cell.2013.08.022. 
Yang, Yanfang, Yu He, Xixi Wang, Ziwei Liang, Gu He, Peng Zhang, Hongxia Zhu, Ningzhi 
Xu, and Shufang Liang. 2017. «Protein SUMOylation Modification and Its 
Associations with Disease». Open Biology 7 (10). 
https://doi.org/10.1098/rsob.170167. 
Yasuda, Makiko, and Robert J. Desnick. 2019. «Murine Models of the Human Porphyrias: 
Contributions toward Understanding Disease Pathogenesis and the 
Development of New Therapies». Molecular Genetics and Metabolism 128 (3): 
332-41. https://doi.org/10.1016/j.ymgme.2019.01.007. 
Zhao, Jicheng, Min Wang, Luyuan Chang, Juan Yu, Aoqun Song, Cuifang Liu, Wenjun 
Huang, et al. 2020. «RYBP/YAF2-PRC1 Complexes and Histone H1-Dependent 
Chromatin Compaction Mediate Propagation of H2AK119ub1 during Cell 






























Ana Talamillo, Orhi Barroso-Gomila, Immacolata Giordano, Leiore Ajuria, Marco Grillo, 
Ugo Mayor, Rosa Barrio. The Role of SUMOylation During Development. Biochemical 
Society Transaction. 2020 Apr 29;48(2):463-478. doi: 10.1042/BST20190390. 
 
ABSTRACT 
During the development of multicellular organisms, transcriptional regulation plays an 
important role in the control of cell growth, differentiation and morphogenesis. 
SUMOylation is a reversible post-translational process involved in transcriptional 
regulation through the modification of transcription factors and through chromatin 
remodelling (either modifying chromatin remodelers or acting as a 'molecular glue' by 
promoting recruitment of chromatin regulators). SUMO modification results in changes 
in the activity, stability, interactions or localization of its substrates, which affects 
cellular processes such as cell cycle progression, DNA maintenance and repair or 
nucleocytoplasmic transport. This review focuses on the role of SUMO machinery and 
the modification of target proteins during embryonic development and organogenesis 
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Townes-Brocks syndrome (TBS) is characterized by a spectrum of malformations in the 
digits, ears, and kidneys. These anomalies overlap those seen in a growing number of 
ciliopathies, which are genetic syndromes linked to defects in the formation or function 
of the primary cilia. TBS is caused by mutations in the gene encoding the transcriptional 
repressor SALL1 and is associated with the presence of a truncated protein that localizes 
to the cytoplasm. Here, we provide evidence that SALL1 mutations might cause TBS by 
means beyond its transcriptional capacity. By using proximity proteomics, we show that 
truncated SALL1 interacts with factors related to cilia function, including the negative 
regulators of ciliogenesis CCP110 and CEP97. This most likely contributes to more 
frequent cilia formation in TBS-derived fibroblasts, as well as in a CRISPR/Cas9-
generated model cell line and in TBS-modeled mouse embryonic fibroblasts, than in 
wild-type controls. Furthermore, TBS-like cells show changes in cilia length and 
disassembly rates in combination with aberrant SHH signaling transduction. These 
findings support the hypothesis that aberrations in primary cilia and SHH signaling are 
contributing factors in TBS phenotypes, representing a paradigm shift in understanding 
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Breast cancer remains one of the leading causes of cancer mortality among women. It 
has been proved that the onset of cancer depends on a very small pool of tumor cells 
with a phenotype similar to that of normal adult stem cells. Cancer stem cells (CSC) 
possess self-renewal and multilineage differentiation potential as well as a robust ability 
to sustain tumorigenesis. Evidence suggests that CSCs contribute to chemotherapy 
resistance and to survival under hypoxic conditions. Interestingly, hypoxia in turn 
regulates self-renewal in CSCs and these effects may be primarily mediated by hypoxic 
inducible factors (HIFs). Recently, microRNAs (miRNAs) have emerged as critical players 
in the maintenance of pluripotency and self-renewal in normal and cancer stem cells. 
Here, we demonstrate that miR-24 is upregulated in breast CSCs and that its 
overexpression increases the number of mammospheres and the expression of stem cell 
markers. MiR-24 also induces apoptosis resistance through the regulation of BimL 
expression. Moreover, we identify a new miR-24 target, FIH1, which promotes HIFα 
degradation: miR-24 increases under hypoxic conditions, causing downregulation of 
FIH1 and upregulation of HIF1α. In conclusion, miR-24 hampers chemotherapy-induced 
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